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ABSTRACT OF DISSERTATION 
 
 
THE LINKAGE BETWEEN TRANSCRIPTION CONTROL AND EPIGENETIC 
REGULATION: THE SNAIL STORY AND BEYOND 
 
 Epigenetic deregulation contributes significantly to the development of multiple 
human diseases, including cancer. While great effort has been made to elucidate the 
underlying mechanism, our knowledge on epigenetic regulation is still fragmentary, an 
important gap being how the diverse epigenetic events coordinate to control gene 
transcription. In the first part of our study, we demonstrated an important link between 
Snail-mediated transcriptional control and epigenetic regulation during cancer 
development. Specifically, we found that the highly conserved SNAG domain of Snail 
sequentially and structurally mimics the N-terminal tail of histone H3, thereby functions 
as a molecular “hook”, or pseudo substrate, for recruiting histone lysine specific 
demethylase 1 (LSD1) repressor complex to the E-cadherin promoter. Furthermore, we 
showed that Snail and LSD1 are both required for E-cadherin repression and EMT 
induction, and their expression is highly correlated with each other in multiple human 
tumor tissues.  
 Our findings have important clinical ramifications in that compounds mimicking the 
SNAG domain may disrupt Snail-LSD1 interaction and inhibit EMT and metastasis. In 
the second part of our study, we designed a batch of compounds based on the structure of 
the SNAG domain and are currently screening for candidates capable of competing with 
SNAG peptide for LSD1 binding. In addition, we applied a peptide pulldown/mass 
spectrometry-coupled analysis to identify SNAG-interacting proteins, among which are 
many chromatin enzymes and modulators. Functional characterization of these proteins 
will help to elucidate the Snail-mediated epigenetic regulation process.  
 In the third part of our study, we found that Snail interacts with poly(ADP-ribose) 
polymerase 1 (PARP1) through a potential pADPr-binding motif and is subject to 
poly(ADP-ribosyl)ation, which can stabilize the Snail-LSD1 complex for enhanced 
PTEN suppression under DNA damage condition. Our findings added another layer to 
the delicate Snail transcriptional machinery, and indicated that PARP inhibitors may be 
applied in combination with conventional chemotherapies to target cancers with high 
expression of Snail and LSD1.  
 In summary, we demonstrated that Snail cooperates with multiple epigenetic 
machineries to induce EMT as well as survival of tumor cells. Our findings contribute to 
a better appreciation of Snail-mediated epigenetic network as well as diversification of 
therapeutic strategies against cancer.  
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Chapter 1: Introduction 
1-1 Overview of epigenetics  
Coined as early as 1942, the term “epigenetics” is undoubtedly showing its popularity 
nowadays 1. While the field of genetics focuses on the study of inherited genes, 
epigenetics deals with the issue beyond the genetic code: the epigenetic code, which has 
been introduced to describe the determinants of gene features other than the changes in 
DNA sequence 2-4. More specifically, within this immense field we are looking into 
processes such as DNA/RNA methylation, protein modifications and chromatin structure 
remodeling, and digging out the underlying mechanisms of how they work in cooperation 
to regulate gene expression. With the advancing knowledge in epigenetics, we have been 
able to better appreciate the diversity and delicacy of gene expression regulation, which 
makes every single creature in one species distinct and unique. 
1-1-1 Epigenetic regulation is a dynamic process   
1-1-1-1 DNA methylation 
 The epigenetic information is maintained/regulated through a dedicate system 
highlighted by DNA methylation and histone modifications 5-7. While histone 
modifications generate reversible local chromatin structures, DNA methylation provides 
reinforcement as well as establishment of gene silencing by keeping chromatin in a 
relatively stable long-term repression state 6. At the molecular level, DNA methylation 
refers to the transfer of a methyl group to the 5 position of cytosine on CpG dinucleotide. 
It was first described in 1948 8 and has since been proved to happen in 60-90% of all 
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CpG sequences in vertebrate genomes, with the exception of CpG islands found in the 
gene promoters 9. During normal development as well as disease progression (more 
discussion below), the CpG islands on specific promoters become methylated, keeping 
the corresponding genes from transcription. Mechanistically, promoter methylation 
confers the gene silencing effect by either directly impeding the approaching of specific 
transcription activators to the promoter area or facilitating the recruitment of corepressor 
complexes through methyl-CpG binding domain proteins (MBPs) 10,11.  
 DNA methylation is catalyzed by two classes of DNA methyltransferases, namely de 
novo methylase (DNMT3A and DNMT3b) and maintenance DNA methyltransferase 
(DNMT1) 12. As their names imply, the former group can create methylation on 
unmodified CpG sequences and is thus responsible for the establishment of DNA 
methylation patterns 13,14, while the latter is required for the preservation of DNA 
methylation through replication 15,16. Although DNA methylation has long been 
considered as a stable epigenetic silencing mark, it is in fact under dynamic regulation 
through passive or active mechanisms. Passive DNA demethylation may occur in absence 
of the maintenance activity of DNMT1 during DNA replication. Active DNA 
demethylation, by contrast, involves enzymatic removal of the methyl group. There are 
several potential mechanisms of active DNA demethylation, including (1) DNA 
glycosylase-mediated 5-methylcytosine (5meC) excision 17,18, (2) cytidine deaminase-
mediated deamination of 5meC to thymine followed by base excision repair (BER) to 
correct the thymine/guanosine mismatch 19,20, (3) direct removal of 5meC-containing 
DNA lesions through nucleotide excision repair (NER) 21, (4) elongator complex protein 
3 (ELP3)-mediated paternal genome demethylation 22,23, and (5) the ten-eleven 
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translocation (TET) family proteins-mediated hydrolysis of 5meC to 
hydroxymethylcytosine (5hmC), which could be subsequently converted to cytosine 24,25. 
While extra evidence is still needed to confirm the mechanisms of active DNA 
demethylation as mentioned above, it is possible that a certain mechanism dominates in a 
biological context-dependent manner. 
1-1-1-2 Histone modifications  
 In the eukaryotic nucleus, DNA is packaged with core histones and other 
chromosomal proteins to form chromatin 26-28. The basic repeating unit of chromatin, the 
nucleosome, is composed of two copies of each of the four core histones, H2A, H2B, H3 
and H4, wrapped by 146 base pairs of DNA 26-28. While it has been over a century since 
histones were discovered, only recently did we begin to appreciate their roles in 
transcription regulation 29. Of note, the “histone code” hypothesis was introduced one 
decade ago suggesting genetic information be regulated in part by histone modifications 
2,30. Structurally, each histone protein contains a central globular domain flanked by N-
and C-terminal tails. The histone tails are subject to a wide variety of post-translational 
modifications, such as phosphorylation, acetylation, ubiquitination and methylation, as 
well as their counterparts, i.e. dephosphorylation, deacetylation, deubiquitination and 
demethylation. Carried out by the corresponding enzymes on specific amino acid 
residues, these modifications function to affect histone-DNA affinity and chromatin 
structure, and provide docking sites for nuclear proteins with further chromatin structure 
modulation or transcription regulation activities, in such a way that they present and 
orchestrate epigenetic information to manipulate gene expression 31.  
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 Unlike DNA methylation that is generally linked to gene silencing, the much more 
variable histone modifications could direct gene expression to go either ways. 
Particularly, acetylation and methylation, as well as their counterparts, i.e. deacetylation 
and demethylation, play essential roles in conferring genes with specific transcriptional 
potential 5. Histone acetylation and deacetylation are mediated by histone 
acetyltransferases (HATs) and deacetylases (HDACs), respectively. While acetylation 
introduces an “open chromatin” state and increases the accessibility of transcription 
complexes, deacetylation does exactly the opposite to impede gene transcription 32. In 
terms of histone methylation/demethylation, things become more complicated. For 
example, methylations on histone H3 lysine 4, 36 and 79 are generally considered as 
transcription activation marks, whereas methylations on histone H3 lysine 9 and 27 are 
linked to transcription repression 33. In addition to acetylation and methylation, histone 
phosphorylation has been demonstrated to affect chromatin structure and play a critical 
role in cell division and apoptosis 34,35. Histone modifications are dynamically regulated 
by specific enzymes and their cofactors 36-40. One typical example is histone 
demethylation carried out by two classes of demethylases: the Jumonji C (JmjC) domain-
containing proteins and the amine oxidases such as LSD1 (more discussion below).   
1-1-2 Crosstalk among DNA methylation and histone modifications  
 There are abundant histone modifications particularly clustered on the relatively 
unstructured tails, making it possible for these modifications to influence one another. 
For example, a lysine residue is subject to different modifications including acetylation, 
methylation, ubiquitination and sumoylation, and these modifications on this particular 
5 
 
residue are mutually exclusive. In addition, a modification on a certain residue may either 
hinder or facilitate the access of chromatin enzymes to the adjacent residues 41,42.  
 It has also been established that DNA methylation and diverse histone modifications 
are interdependent events with specific hierarchies and/or feedback loops 6,43-45. On one 
hand, a specific histone modification pattern would predispose DNA methylation. 
Basically, as an initial step in gene repression, removal of methylation on histone H3 
lysine 4 (H3K4) releases the inhibitory effect on the approaching of DNMT3a and 
DNMT3b to the nucleosome, therefore presetting a welcome environment for de novo 
DNA methylation to take place 46. Subsequently, deacetylation of histone H3/H4 
facilitates the binding of histone methyltransferases such as G9a and SUV39H1, which 
use different mechanisms to further promote the recruitment of de novo DNA 
methyltransferases (more discussion below) 6. On the other hand, once the pattern of 
DNA methylation has been set, it serves as a template for the reconstruction of epigenetic 
state during the cell differentiation process. Indeed, there are previous studies 
demonstrating that methyl-CpG-binding domain proteins (MBDs) residing in the 
chromatin region mediate the recruitment of HDACs; in addition, DNA methylation 
predisposes H3K9 dimethylation (H3K9me2) while excluding methylation on H3K4 47,48. 
The detailed mechanism of how these epigenetic events influence each other remains 
incompletely understood.  
1-1-3 Epigenetic regulation in development and disease progression 
 During development, the phenotype of each individual is determined not only by 
genetic information, but also by epigenetic parameters. For the appropriate execution of 
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developmental programs which seek to reach the balance between dynamic cell 
reprogramming and stable homeostasis, it is necessary that the whole epigenetic 
machinery function properly. Epigenetic regulation is involved in events such as genomic 
imprinting 49, X-chromosome inactivation 50,51, cell lineage restriction 52 and tissue 
terminal differentiation 53. As a typical example, the Polycomb group (PcG) and the 
trithorax group (trxG) proteins function to maintain the spatial expression of Hox genes, 
which are critical in the determination of anterior/posterior patterning during early 
embryonic development. PcG is composed of two complexes: Polycomb repressive 
complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2). PRC2 represses Hox 
genes expression by exertion of histone H3 lysine 27 trimethylation (H3K27me3) and 
recruitment of DNMTs, while PRC1 imposes silencing through chromatin remodeling 
inhibition and histone H2A ubiquitination 54-56.  As the mechanistic counterpart of PcG, 
trxG binds the same chromosomal elements and maintains Hox genes expression through 
its component Ash1, which deposits transcriptional activation mark histone H3 lysine 4 
trimethylation (H3K4me3) 57,58. It has been indicated that PcG and trxG cooperate to 
regulate the expression of critical genes involved in embryonic stem (ES) cells 
maintenance and differentiation 59,60.  
 The epigenetic landmark is regulated in such a sophisticated fashion that disruption of 
the balance of epigenetic stage, either at the genome scale or even restricted to a certain 
gene, is usually the cause of many diseases, including but not limited to diabetes 61, 
asthma 62, neuronal disorder 63 and cancer 64-66. The very first case was documented in 
1983 when researchers found an aberrant level of DNA methylation in colorectal cancer 
patient tissues 67. Since then, a growing number of studies have demonstrated the 
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contribution of abnormal DNA methylation to human diseases 68, a couple of cancer-
related examples being (1) promoter hypermethylation and therefore silencing of tumor 
suppressor p16 frequently found in multiple human carcinomas 69, and (2) promoter 
hypomethylation and aberrant activation of HRAS oncogene in primary human cancers 70.  
 Besides DNA methylation, the far more diversified histone modifications play crucial 
roles in epigenetics and are often misrepresented in human diseases. The disease-causing 
histone modification patterns are reminiscent of anomalous chromatin regulator activities 
71-73. For instance, overexpression of histone lysine specific demethylase 1 (LSD1) has 
been correlated to malignant progression of prostate cancer, neuroblastoma and estrogen 
receptor (ER)-negative breast cancers (more discussion below) 74-77. In a recent study, 
Jiao and colleagues identified common genetic mutations in pancreatic neuroendocrine 
tumors, including mutations in MEN1 that encodes the transcription factor Menin being 
able to recruit the histone H3K4 methyltransferase mixed-lineage leukemia (MLL) 
complex; and mutations in ATRX and DAXX that encode proteins to form a complex 
harboring chromatin-remodeling adenosine triphosphatase activity 78,79.  
1-1-4 Epigenetic modifications as therapeutic targets 
 As mentioned above, epigenetic deregulation is almost always associated with human 
diseases. Accordingly, epigenetic therapy, which aims to correct these defects by 
targeting specific epigenetic regulators, has emerged as a promising area of 
pharmacology given the fact that unlike genetic alterations, epigenetic aberrations are 
potentially reversible 80-82. In 2004, Azacitidine, with the trade name Vidaza, became the 
first FDA-approved epigenetic drug to treat bone-marrow cancer and blood disorder 83. It 
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is a cytidine analog and functions as a potent inhibitor of DNA methyltransferases. In 
addition to Azacitidine, cytidine analogs with similar working mechanism include 
Dacogen 84 and Zebularine 85. Notably, DNA methylation inhibitors in combination with 
conventional chemotherapy drugs have shown promising anti-cancer effects 86-88. The 
enhanced tumor cell killing effect may lie in the reactivation of proapoptotic genes 
through reversal of promoter DNA methylation. Despite the clinical success as mentioned 
above, inhibition of DNA methylation could have controversial results according to the 
following concerns: (1) global decrease of DNA methylation following treatment of 
DNA methylation inhibitors may unexpectedly activate the expression of oncogenes 
and/or cause genomic instability; (2) since DNA methylation inhibitors exert their 
function during DNA replication, they are cell-cycle dependent and may be not as 
effective in treating diseases without rapid cell cycling; (3) DNA methylation inhibitors 
have shown certain toxicity and the level of DNA methylation may bounce back after 
drug withdrawal. Together, these limitations leave room for future improvement of 
therapies.  
 Besides DNA methylation inhibitors, innovative drugs targeting enzymes involved in 
histone modifications are under development. Vorinostat (Zolinza, formerly known as 
SAHA), for example, is a histone deacetylase inhibitor that was approved by the FDA in 
2006 to treat the rare cancer cutaneous T cell lymphoma (CTCL) 89. Since then, research 
has endeavored to investigate more histone deacetylase inhibitors, several of which have 
been through clinical or preclinical tests 82,90. Furthermore, novel histone 
methyltransferase and demethylase inhibitors are currently under intense investigation 
and will hopefully enter clinical trials in the near future (more discussion below) 91,92. In 
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summary, the importance of epigenetic regulation during development, as well as the 
dynamic nature of epigenetic landscape per se, renders epigenetic therapy a promising 
research field for the cure of a variety of diseases. With the advancing technologies such 
as genome-wide sequencing in combination with chromatin immunoprecipitation (ChIP), 
bisulfite conversion or RNA profiling, more comprehensive data will be attained for the 
identification of critical epigenetic regulators as therapeutic targets.  
1-2 Overview of the zinc finger transcription factor Snail   
 Snail is the leading member of the Snail family of zinc-finger transcription factors, 
which also contain Slug (Snail2) and Smuc (Snail3) 93. It was first identified in 
Drosophila as a suppressor of shotgun (an E-cadherin homologue) 93,94. Snail plays a 
central role in morphogenesis, as it regulates the formation of the mesoderm and neural 
crest in species ranging from flies to mammals 93-95. Absence of Snail is embryonic lethal 
due to severe developmental defects at the gastrula stage 96.  
 Structurally, Snail family members share a highly conserved carboxy-terminal region 
containing four to six C2H2-type zinc fingers, which recognize specific E-box sequence 
(CAGGTG) present in target gene promoters. The amino-terminal region of all vertebrate 
Snail family members contains an evolutionally conserved SNAG (Snail/Gfi) domain, 
which along with the zinc finger region accounts for the transcriptional repression 
activity of the proteins. For Drosophila Snail, while the SNAG domain is absent, it 
contains a consensus PxDLSx motif that can interact with a co-repressor CtBP (carboxy-
terminal binding protein) for the exertion of transcription repression 93.  
 
10 
 
1-2-1 Snail plays essential roles during cancer development 
1-2-1-1 Snail and epithelial-mesenchymal transition (EMT) 
 EMT is initially recognized as a process vital for mesoderm formation in Drosophila 
and mammals 97. During EMT, epithelial cells lose their ability to adhere to each other, 
gain fibroblast-like properties and become more mobile 98-100. The migratory nature of 
these transformed cells is reminiscent of the characteristics of metastatic tumor cells. 
Indeed, there has been strong evidence suggesting that EMT is an early event during 
invasion and metastasis of many carcinomas 101,102. EMT of tumor cells can be induced 
upon receipt of microenvironmental stimuli such as tumor growth factor β (TGF-β), Wnt 
and tumor necrosis factor-α (TNF-α) 103-107. It confers tumor cells not only with the 
capability to migrate and invade, but also with stem cell-like properties, which largely 
account for immunosuppression and tumor recurrence 108-111.  
 As a commanding cellular event during embryogenesis and tumor progression, EMT 
has been a long-time research interest in the field of molecular biology. A hallmark of 
EMT is loss of E-cadherin expression 112,113. E-cadherin is a cell-cell adhesion molecule 
that is involved in the formation of epithelial adherent junctions 114. Along with several 
other transcription factors such as Slug, Twist and ZEB1/2, Snail is well known for the 
role of E-cadherin suppression and EMT induction 113,115-118. Remarkably, Snail protein is 
overexpressed in both epithelial and endothelial cells of invasive breast cancer compared 
to normal tissues 119,120, and its expression correlates with the degree of metastasis and 
predicts a poor outcome of patients with breast cancer 121-123.  
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1-2-1-2 Snail and tumor cell survival 
 In addition to EMT induction, Snail regulates cell cycle progression and survival. 
Snail expression has been demonstrated to confer chemoresistance on breast, colon, lung 
and pancreatic cancer cells 124-127. Snail protects cells from death probably through 
transcriptional repression of proapoptotic genes. For example, Snail has been 
demonstrated to repress the transcription of a subset of genes required for p53-mediated 
apoptosis 128; Snail promotes cell survival against genotoxic stress through BID and 
caspase-6 repression 129; Snail also directly inhibit PTEN transcription to render cell 
resistant to γ radiation-induced apoptosis (more discussion below) 130. Interestingly, Snail 
has been shown to block G1 entry and G1/S transition during cell cycle by repressing 
Cyclin D2 while maintaining high level of p21 expression 131. This seems paradoxical 
since the cyclin-dependent kinase inhibitor p21 is previously known as a proliferation 
inhibitor and plays an important role in preventing tumor development 132. Recent 
studies, however, found that in addition to its function as a tumor suppressor, p21 also 
exerts oncogenic role by inhibiting apoptosis 133. Based on these findings, it is possible 
that Snail enhances p21 expression to block cell cycle progression in response to cellular 
stress and damage, which permits DNA repair to proceed for tumor cell survival.    
 Together, Snail plays multifunctional roles in tumor survival and progression. In fact, 
it not only promotes EMT and inhibits apoptosis, but also induces immunosuppression 134 
and maintains the properties of cancer stem cells (CSCs) 128,135. As Snail remains an 
intense research interest in the field of cancer biology, more mechanistic details will be 
clarified for a thorough understanding of its roles during these processes; furthermore, the 
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association of Snail with some yet-to-known cellular events could also be discovered in 
the near future.  
1-2-2 Snail is under dynamic regulation 
 Snail is high unstable with a half-life of around 25 minutes 123. The activity of Snail is 
mainly dependent on its protein stability as well as cellular location. Basically, glycogen 
synthase kinase-3β (GSK-3β) can phosphorylate Snail at two consensus motifs to 
respectively mediate its nuclear export and β-Trcp-mediated protein ubiquitination and 
degradation 123. Activation of receptor tyrosine kinases such as epidermal growth factor 
receptor (EGFR) and fibroblast growth factor receptor (FGFR) can initiate signaling 
cascades leading to GSK-3β suppression and Snail expression 136. In contrast to GSK-3β, 
p21-activated kinase 1 (PAK1) phosphorylates Snail at different lysine residues in favor 
of its nuclear localization 137. Furthermore, several critical pathways are involved in the 
regulation of Snail. (1) TGF-β induces Snail expression through SMAD signaling 
activation 136. (2) Ras enhances Snail expression in a MAPK and phosphatidylinositol 3-
kinase (PI3K)-dependent manner 138,139. (3) Notch signaling mediates Snail upregulation 
through direct binding of the Notch intracellular domain to Snail promoter. Alternatively, 
Notch signaling can induce the recruitment of hypoxia-inducible factor 1α (HIF1α) to 
lysyl oxidase (LOX) promoter for transcription activation. LOX then mediates Snail 
oxidation, which masks the GSK-3β-dependent regulatory motif 140. (4) NFκB can 
directly bind Snail promoter for transcription activation 141. Alternatively, NFκB 
signaling can induce the transcription of COP9 signalosome 2 (CSN2), which functions 
to block the interaction of Snail with GSK-3β/β-Trcp and stabilize the protein 103. 
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Currently, an interesting notion is that histone-modifying enzymes can switch their 
substrates from histones to non-histone proteins such as transcription factors and 
enzymes (more discussion below). It remains to be seen if Snail is subject to 
modifications by some of these enzymes, and how these potential modifications may 
affect its protein stability as well as its function as a transcription repressor.  
1-3 Linkage between Snail-mediated transcriptional control and epigenetic 
regulation: hypothesis and research aims 
 As mentioned, overactivation of Snail is intimately associated with the development 
of a variety of cancers, many of which may concurrently harbor aberrant epigenetic 
landscape. It will be interesting to find out if there is any linkage between Snail-mediated 
transcriptional control and epigenetic regulation during cancer development. According 
to the chromatin “reader and writer” idea, as a transcription factor, Snail is able to “read” 
its target gene promoters using the DNA-binding zinc fingers; however, Snail does not 
have chromatin modulation activity and falls short of “writing” epigenetic marks on 
either DNA or histones. It is hypothesized that transcription factors (as chromatin 
readers) can cooperate with chromatin enzymes/modulators (as chromatin writers) to 
regulate gene transcription. Indeed there have been emerging research data demonstrating 
that Snail can recruit different chromatin-modifying proteins to its target gene promoters 
for transcription repression (more details below). However, the specific mechanisms 
governing these processes remain only partially understood, a key question being how 
Snail orchestrates multiple epigenetic events to promote tumor development.  
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 Clearly, exploration of the Snail protein interaction network will help us better 
appreciate this typical epigenetic story. To achieve this goal, we recently applied an 
affinity purification-mass spectrometry coupled analysis to identify Snail-interacting 
proteins (more details below). Among the proteins we identified, lysine-specific 
demethylase 1 (LSD1) and poly(ADP-ribose) polymerase 1 (PARP1) 142 are two 
interesting candidates due to their chromatin-modifying roles and, more importantly, their 
involvement in tumor development. Based on our preliminary finding as well as those of 
previous studies, we hypothesized that Snail cooperates with LSD1 and/or PARP1 to 
exert its functions such as EMT induction and apoptosis inhibition. Two of prominent 
Snail target genes are E-cadherin and PTEN, which respectively represent an important 
indicator of EMT and cell apoptosis. Through our study, we aimed to clarify how LSD1 
and PARP1 are potentially involved in Snail-mediated E-cadherin and PTEN 
suppression, and tried to exploit the underlying clinical indications for the development 
of novel epigenetic therapies.   
 
 
 
 
 
Copyright © Yiwei Lin 2012 
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Chapter 2: The SNAG domain of Snail functions as a molecular hook for recruiting 
LSD1 
2-1 Introduction 
 As mentioned, EMT confers cancer cells with the distinct advantages of invasion and 
metastatic dissemination 99,143. Interestingly, EMT is a reversible process 144,145. When 
cancer cells disseminate to distant sites in the body, they no longer encounter the signals 
that they experienced in the primary tumor and can revert to an epithelial state by a 
mesenchymal–epithelial transition (MET). The phenotypic plasticity of cancer cells 
during EMT/MET indicates the involvement of an epigenetically regulated differentiation 
program, which remains to be elucidated 146.  
 Snail is a master regulator of EMT, remarkably through transcriptional repression of 
E-cadherin 93,94 . For vertebrate Snail proteins, the SNAG domain at the amino-terminal 
region is required for their repressor activity 93. According to the chromatin “reader and 
writer” idea as mentioned above, Snail may cooperate with chromatin-modifying 
enzymes/cofactors to repress its target genes transcription. It was hypothesized that 
SNAG domain functions as a linker to bridge Snail and multiple chromatin “writers” 
together. The first evidence came from studies of Peinado and colleagues. They 
demonstrated that mouse Snail uses its SNAG domain to associate with HDAC1/2 and 
corepressor mSin3A, and recruits the repressor complex to E-cadherin promoter, where 
HDAC1/2 deacetylate histone H3 and H4 to create the repressive chromatin environment 
147. Treatment of cells with histone deacetylase inhibitor Trichostatin A (TSA) efficiently 
abolished the repressive effect of Snail 147. Based on previously studies demonstrating the 
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connection and mutual communication between histone deacetylation and DNA 
methylation 148-151, they hypothesized that HDACs-mediated histone deacetylation helps 
to maintain promoter DNA methylation and gene silencing of E-cadherin.  Furthermore, 
Peinado and colleagues found that the level of histone H3 lysine 9 dimethylation 
(H3K9me2), which is a transcription repression mark, was increased at the E-cadherin 
promoter region upon overexpression of Snail in epithelial cells, indicating the 
involvement of other repressor complexes containing histone methyltransferase activities 
during the regulation process 147.   
 Herranz and colleagues have recently demonstrated the recruitment of PRC2 by Snail 
to E-cadherin promoter, providing a second example for Snail-mediated epigenetic 
regulation machinery 152. As mentioned above, PRC2 contains methyltransferase activity 
on histone H3 lysine 27, and functions to initiate the transcription silencing process 153. 
Herranz and colleagues found that PRC2 was required for Snail-mediated E-cadherin 
suppression, as knockdown of essential PRC2 components Suz12 or Ezh2 abolished the 
suppressive effect of Snail in pancreatic cancer cell line RWP-1 as well as colon 
adenocarcinoma cell line SW-620 152. While the interaction between Snail and PRC2 
could be either direct or indirect, they demonstrated the necessity of the SNAG domain of 
Snail for recruiting PRC2 152. Other than their studies, researches from two independent 
groups showed that the SNAG domain of Snail could interact with both the Ajuba LIM 
and PRMT5 proteins, the latter of which then associated with Suz12 (the enzymatic 
component of PRC2) through a mediator MEP50 154,155. Based on these results, it seems 
likely that the SNAG domain of Snail recruits PRC2 in an Ajuba/PRMT5-dependent 
fashion. While still in seek of comprehensive supporting data, Herranz and colleagues 
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suggested another possibility that the interaction of Snail with PRC2 is mediated by 
HDACs, according to previous studies showing that HDACs can associate with both 
Snail and PRC2, and that histone deacetylation supports PcG-mediated transcription 
suppression 156,157.   
 Together, earlier studies have strongly indicated the crucial role of Snail on 
epigenetic silencing of E-cadherin, typically through recruiting multiple repressor 
complexes to the E-cadherin promoter region. Recently, we undertook the unbiased 
approach of tandem array purification (TAP) coupled with mass spectrometry analysis to 
identify chromatin-modifying enzymes that interact with Snail. We found that Snail 
interacted with LSD1, a key component of several co-repressor complexes including 
CoREST, CtBP and HDAC1/2 33. As the first identified histone demethylase, LSD1 
functions by specifically removing methylation marks on H3K4 and initiating the 
transcription repression process 158,159. Previous studies have established that LSD1 can 
cooperate with different transcription factors to selectively repress gene transcription 160-
163. Most importantly, LSD1 plays an essential role during development, and 
overexpression of LSD1 has been correlated with malignant progression of multiple 
cancers, including primary neuroblastic tumors, prostate cancer, and ER-negative breast 
cancer 74-77. In our study, we further characterized the functional interaction of Snail with 
LSD1 and investigated their roles in mediating chromatin modification during metastasis. 
Notably, we suggested a model illustrating that Snail uses its SNAG domain as a 
molecular “hook”, or pseudo substrate, to recruit LSD1.  
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2-2 Materials and methods 
Antibodies and plasmids 
 Human cDNA for LSD1 and CoREST was amplified from HeLa cDNA and cloned 
into pCMV-Tag2B and pcDNA3 with the N-terminal Flag or HA tag, respectively. 
Deletion mutants for LSD1 were generated by PCR and subcloned into the GST 
expression vector pGEX-6P-3-TEV that contains two protease cleavage sites of tobacco 
etch virus. Snail mutants were generated using the QuikChange Mutagenesis kit 
(Stratagene, La Jolla, CA) as described previously 164. All sequences were verified by 
DNA sequencing. Antibodies against Snail, LSD1 and CoREST were purchased from 
Cell Signaling Technology (Danvers, MA). Anti-Flag and anti-HA antibodies were 
obtained from Sigma-Aldrich (St Louis, MO) and Roche Molecular Biochemicals 
(Indianapolis, IN), respectively. An antibody against H3K4me2 was purchased from 
Millipore (Bedford, MA). 
Cell cultures, transfections and reporter assays 
 The human embryonic kidney HEK293, breast cancer MCF7, MDAMB231 and 
SKBR3, prostate cancer PC3 and colon cancer HCT116 cell lines were purchased from 
the American Type Culture Collection (Manassas, VA) and grown in Dulbecco’s 
modified Eagle’s/F12 medium plus 10% fetal bovine serum as described previously 103. 
Lysine-specific demethylase 1, CoREST and Snail were transiently transfected into cells 
using FuGENE 6 (Roche Molecular Biochemicals). For luciferase assay, cells were 
plated in six-well plates at a density of 2×105 cells per well. Cells were transfected with 
0.3 µg of the pGL3–E-cadherin promoter–luciferase plasmid along with 0.1nM of Snail 
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and/or LSD1 siRNA in each well. To normalize transfection efficiency, cells were also 
co-transfected with 0.1 µg of pRL-CMV (Renilla luciferase). At 48 h after transfection, 
luciferase activity was measured using the Dual-Luciferase Assay kit (Promega, 
Madison, WI). Three independent experiments were performed, and the calculated means 
and s.d. values were presented. 
GST pull-down assay 
 Glutathione-S-transferase proteins were expressed as described previously 164. Cells 
were subjected to lysis in GST pull-down buffer (20mM Tris, 150mM NaCl and 1% 
Nonidet P-40 with protease cocktail) and rotated with glutathione–Sepharosebound wild-
type or deletion mutants of GST–LSD1. The binding complexes were eluted with SDS–
PAGE sample buffer. About one tenth of these elutents were analyzed for the association 
of Snail by western blotting and the rest were examined for the presence of purified 
GST–LSD1 by Coomassie staining. 
Histone demethylation assay 
 Mononucleosomes were purified from HeLa S3 nuclear extract 165. The histone 
demethylation assay was performed as described previously using mononucleosomes as a 
substrate 159,166,167. Briefly, HEK293 cells were co-transfected with constructs encoding 
LSD1, CoREST and Snail. After immunoprecipitation of Snail, complexes were 
incubated with mononucleosomes in demethylation buffer (50mM Tris–HCl (pH 8.0), 
50mM KCl, 5mM MgCl2, 2mM DTT with proteasome inhibitors) with or without Parnate 
or Pargyline at 37ºC for 12 h. Reactions were stopped with SDS sample buffer. Western 
blot analysis was performed with an antibody against H3K4me2 (Upstate). The same 
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membrane was then stripped and re-probed with α-histone H3 (Abcam, Cambridge, MA, 
ab1791) as a substrate-loading control. 
Western blot analysis and immunoprecipitation 
 For protein extraction, 5×105 cells per well were plated onto six-well plates and 
transiently transfected with 0.5 mg of pcDNA3-Snail and 0.5 µg of pCMV-Tag2B-LSD1 
or vector. At 48 h after transfection, cells were incubated with or without the proteasome 
inhibitor MG132 (10 µmol/l) for an additional 6 h before protein extraction and western 
blot analysis. Primary antibodies against Flag (M2, 1:1000) and HA (3F10, 1:4000) were 
used for protein detection. For immunoprecipitation, HEK293 cells transfected with the 
indicated expression plasmids were lysed in buffer (50 mmol/l Tris (pH 7.5), 150 mmol/l 
NaCl, 5 mg/ml aprotinin, 1 mg/ml pepstatin, 1% Nonidet P-40, 1 mmol/l EDTA and 
0.25% deoxycholate). Total cell lysates (1000 µl) were incubated overnight with 1 mg of 
anti-HA or anti-Flag antibody conjugated to agarose beads (Roche Molecular 
Biochemicals) at 4ºC. The beads were then washed with lysis buffer, and the 
immunoprecipitated protein complexes were resolved by 10% SDS–PAGE. 
Invasion assay 
 Invasion assays were performed as previous described 103. Briefly, Boyden chambers 
were coated with Matrigel according to the manufacturer’s protocol (BD Biosciences, 
San Jose, CA). Cancer cells were seeded on top of the Matrigel in the upper chamber, and 
the bottom chamber was filled with culture medium containing LPA (10 µM) as the 
chemoattractant. Cells that invade through the Matrigel-coated membrane after 4 or 24 h 
were fixed with paraformaldehyde, followed by staining with crystal violet. All 
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experiments were conducted at least twice in triplicate. Statistical analysis was performed 
with Student’s t-test; a P-value of <0.05 was considered significant. 
Chromatin immunoprecipitation 
 Chromatin immunoprecipitation assays were performed according to the protocol 
described before 168 with some modifications. The cells were crosslinked with 
disuccimidyl glutarate (Pierce, Rockford, IL) and formaldehyde at room temperature. 
Cells were subjected to lysis with L1 buffer (50mM Tris, 2mM EDTA, 0.1% IGEPAL, 
10% glycerol, 1mM dithiothreitol, 1mM phenylmethylsulfonyl fluoride (PMSF) and 
protease inhibitor mixture (pH 8.0)) on ice. After centrifugation, the nuclear pellet was 
resuspended in ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM Tris and protease 
inhibitor mixture (pH 8.0)). Cell lysates were subjected to sonication and then incubated 
with 4 mg of Snail (Abcam) or LSD1 (Sigma-Aldrich) antibody overnight, followed by 
incubation with a 50% slurry of protein A–agarose/Salmon sperm DNA (Upstate 
Biotechnology, Lake placid, NY) for 3 h at 4ºC. Bound DNA–protein complexes were 
eluted and crosslinks were reversed after a series of washes. Purified DNA was 
resuspended in TE buffer (10mM Tris–HCl and 1mM EDTA (pH 8.0)) for PCR. Primers 
for the E-cadherin promoter were 5’-ACTCCAGGCTAGAGGGTCACC-3’ and 5’-
CCGCAAGCTCACAGGTGCTTTGCAGTTCC-3’. 
Immunofluorescence imaging 
 For immunofluorescence microscopy, cells were grown on coverslips, fixed with 4% 
paraformaldehyde and incubated overnight with anti-LSD1 monoclonal antibody. 
Proteins were visualized by incubation with goat anti-mouse conjugated with Alexa Fluor 
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568 (Invitrogen, Carlsbad, CA). Finally, coverslips were incubated with 4’, 6’-diamidino-
2-phenylindole (Sigma-Aldrich) for 20 min and visualized under a fluorescent 
microscope. 
Immunohistochemical staining 
 All the breast tumor samples used in this study are invasive ductal carcinoma. The 
average age for patients in this group is 56.8 (±13.4) years with either negative (53.3%) 
or positive (N1=34.6; N2=12.1%) lymph node metastasis. These samples are of stage I 
(12.5%), stage II (38.2%), stage III (41.1%) or stage IV (8.2%). Tissue samples were 
stained with anti-Snail (1:200 dilution, Abcam), anti-LSD1 (1:150, Abcam) and anti-
CoREST (1:150, BD Biosciences) antibodies, and each sample was scored by an H-score 
method that combines the values of immunoreaction intensity and the percentage of 
tumor cell staining as described previously 103. Chi-square analysis was used to analyze 
the relationship between Snail and LSD1/CoREST expression; statistical significance 
was defined as P<0.05. 
Subcellular fractionation 
 Cytoplasmic and nuclear fractions were prepared as described previously 164. Briefly, 
cultured cells were suspended in buffer A (10mM HEPES (pH 7.9), 1.5mM MgCl2, 
10mM KCl, 0.5mM EDTA and protein inhibitor cocktail) on ice and lysed using a 
Dounce homogenizer. The nuclear pellet was washed and isolated. Nuclei were subjected 
to lysis in RIPA buffer (150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 
50mM Tris (pH 8.0), 25mM NaF, 2mM Na3VO4, 5mM PMSF and 2 µg/ml of aprotinin). 
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Poly (ADP-ribose) polymerase and β-tubulin were used as markers of the nuclear and 
cytoplasmic fractions, respectively. 
Protein model structure 
 The protein modeling analysis was performed by Dr. Young-In Chi, University of 
Kentucky Chandler Medical Center. The three-dimensional (3D) model of the LSD1–
SNAG–Snail complex was built by comparative protein structure modeling using the 
program MODELLER 9v3 169. The input consisted of the template structure and the 
alignment of the target sequence with this structure. The output was a 3D model of the 
target including all non-hydrogen atoms. This model was derived by minimizing 
violations of distance and dihedral angle restraints extracted from the template structure 
while maintaining favorable interactions. The template structure was the LSD1–
CoREST–Histone H3 peptide complex structure (Protein Data Bank, 2V1D).   
2-3 Results 
Snail interacts with LSD1 through the SNAG domain 
 To identify the potential proteins that interact with Snail, Dr. Peter Zhou generated a 
stable HEK293 cell line expressing dual-tagged Snail (Figure 2.1A). After enriching the 
nuclear extracts, we carried out a two-step sequential protein purification process with 
Flag and hemagglutinin (HA) affinity columns 170. The final immunocomplexes were 
separated on SDS–PAGE and subjected to silver staining (Figure 2.1A). Bound proteins 
were excised from the gel and subjected to mass spectrometry analysis. Three known 
proteins that interact with Snail, GSK-3β, β-Trcp and PRMT5 123,154, were found in the 
complexes, which validated the specificity of this system. Lysine-specific demethylase 1 
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33, an H3K4 demethylase, was also identified as a protein that associated with Snail. Six 
trypsin-digested peptides from a protein with a molecular weight of about 110 kDa were 
perfectly matched to the protein sequence of LSD1 (Figure 2.1A). 
 To validate the physical interaction of Snail with LSD1, we co-expressed Snail–HA 
and Flag–LSD1 in HEK293 cells and conducted a co-immunoprecipitation experiment. 
After immunoprecipitating LSD1, we detected the associated Snail, and vice versa 
(Figure 2.1B), indicating that these two molecules are associated. Interestingly, deletion 
of the SNAG (Snail/GFI) domain 93,147,171,172, a highly conserved repressive domain 
present at the N-terminus of several transcription factors (such as Snail and GFI1), 
significantly reduced the interaction of Snail with LSD1, indicating that the SNAG 
domain is required for this interaction (Figure 2.1B). We also immunoprecipitated 
endogenous Snail and LSD1 from PC3, HCT116, MDA-MB 231 and SKBR3 cells and 
detected the presence of endogenous LSD1 and Snail, respectively (Figure 2.1C). 
Consistent with these data, when GFP–Snail was expressed in HEK293 cells, we found 
that Snail was co-localized with endogenous LSD1 in the nucleus (Figure 2.1D). Taken 
together, our results indicate that Snail interacts with LSD1 and that the SNAG domain of 
Snail is required for mediating their interaction.  
The SNAG domain is essential for the stability of Snail 
 In addition to Snail and GFI1, several other transcription factors, such as Slug, 
Scratch, insulinoma-associated protein IA-1 (Insm1) and Ovo-like 1 (OVOL1), also 
contain a similar SNAG domain at their N-terminus (Figure 2.2A). This motif is highly 
conserved among species and is important for the repressive activity of these 
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transcription factors in mammalian cells 93,147,171,172. We, along with others, previously 
showed that Snail is a highly unstable protein and is regulated by protein stability and 
subcellular localization 123,173,174. To test whether the SNAG domain regulates the protein 
stability, subcellular localization, and repressive activity of Snail, we generated a Snail 
mutant with SNAG domain deletion (ΔSNAG–Snail) and a destabilized d2-GFP with 
SNAG domain fused to the N-terminal (SNAG–d2-GFP; Figure 2.2B). Consistent with 
previous findings, deletion of the SNAG domain significantly reduced the repressive 
activity of Snail on the E-cadherin promoter, whereas adding the SNAG domain to d2-
GFP had no effect (Figure 2.2B), suggesting that the SNAG domain is required but is not 
sufficient for the transcriptional repressive activity of Snail. The failure of ΔSNAG-Snail 
to suppress E-cadherin promoter activity was not due to the instability of this molecule, 
as treatment with MG132 did not enhance the suppressive function of this mutant (Figure 
2.2C). Interestingly, ΔSNAG-Snail became less stable than wild-type Snail, whereas 
SNAG-d2-GFP became stabilized in comparison with d2-GFP (Figure 2.2D). To further 
extend this finding, we investigated the degradation of these proteins with treatment of 
the protein synthesis inhibitor, cycloheximide, for various time intervals. We found that 
the protein level of ΔSNAG–Snail significantly decreased after 1 h in comparison with 
that of wild-type Snail (Figure 2.2E). In contrast, SNAG–d2-GFP became more stable 
than d2-GFP (Figure 2.2F), indicating that the SNAG domain is critical for maintaining 
the protein stability of Snail, in addition to its transcriptional repressive function. 
 We next examined whether the SNAG domain affects the subcellular location of 
these proteins. Although the intensity of SNAG–d2-GFP was enhanced because of its 
increased stability, d2-GFP and SNAG–d2-GFP were distributed equally in the nucleus 
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and cytoplasm (Figure 2.3A). We also expressed wild-type Snail– and ΔSNAG–Snail–
GFP in HEK293 cells and found that both were localized predominantly in the nucleus 
(Figure 2.3B). Although ΔSNAG–Snail has significantly decreased protein stability, the 
loss of the SNAG domain did not affect its nuclear localization. We also performed 
subcellular fractionation analysis and found that the addition or deletion of the SNAG 
domain did not change the subcellular localization of d2-GFP or Snail, respectively 
(Figure 2.3C). Taken together, our results indicate that the SNAG domain is critical in 
controlling the protein stability but not the subcellular location of Snail. 
The SNAG domain of Snail interacts with LSD1 by mimicking the structure of the 
histone H3 tail 
 We also expressed d2-GFP and SNAG–d2-GFP in HEK293 cells. 
Immunoprecipitation of SNAG–d2-GFP, but not of d2-GFP, revealed the association of 
endogenous LSD1, indicating that the SNAG domain is sufficient for Snail to interact 
with LSD1 (Figure 2.4A). Lysine-specific demethylase 1 is a demethylase for H3K4me2 
33. Although it can bind to the histone H3 tail for demethylation, it does not contain a 
DNA-binding motif. The manner in which LSD1 binds to a specific promoter chromatin 
remains unclear. The X-ray structure of the LSD1–CoREST–Histone H3 peptide 
complex has been determined 175,176, showing that residues of Arg2, Thr6, Arg8, Lys9 
and Thr11 of histone H3 (highlighted with blue dots at the top of Figure 2.4B) are critical 
for establishing the contact interactions of histone H3 within the catalytic cavity of LSD1. 
We noticed that the sequence of the SNAG domain is highly similar to that of the N-
terminus of histone H3 and contains arginine- and lysine-rich residues (Figure 2.4B). 
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Interestingly, the SNAG domain of Snail contains almost identical residues at four of 
these five positions (Arg3, Arg8, Lys9 and Ser11). To identify the critical residues on the 
SNAG domain required for interaction with LSD1, we performed alanine scan 
mutagenesis on the SNAG domain of Snail (Figure 2.4C). Among the 15 Snail mutants 
screened, we found that mutations at Pro2, Arg3, Lys9 and Pro10 decreased the protein 
stability of Snail (Figure 2.4C). However, treatment with proteasome inhibitor, MG132, 
restored the protein stability of these mutants, indicating that these four residues are 
critical for controlling the protein stability of Snail. This is consistent with the finding 
that the SNAG domain is important for the protein stability of Snail (Figure 2.2). Similar 
to the SNAG deletion mutant of Snail, mutation of these four residues did not alter the 
nuclear localization of Snail (Figure 2.4D). 
 We next examined the interaction of these 15 mutants with LSD1 by 
immunoprecipitating endogenous LSD1. We found that Pro2, Arg3, Ser4, Phe5, Arg8 
and Lys9 mutants completely lost their ability to interact with LSD1 (Figure 2.4E). The 
loss of interaction of these mutants with LSD1 was not due to the instability of these 
mutants, as cells were treated with the proteasome inhibitor, MG132, to prevent Snail 
from degradation. Consistent with these data, when Snail was immunoprecipitated, the 
association of these mutants with LSD1 was also abolished (Figure 2.4E). Interestingly, 
mutants that cannot interact with LSD1 also lost their ability to inhibit E-cadherin 
promoter luciferase activity, suggesting that the interaction with LSD1 is critical for the 
suppressive function of Snail (Figure 2.4F). 
 We also performed protein modeling analysis on the basis of the structure of the 
LSD1–CoREST–Histone H3 complex. We found that the SNAG domain of Snail adopted 
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a conformation that was superimposed by the histone H3 tail at the catalytic cavity of 
LSD1 (Figure 2.4G). Noticeably, Arg3, Arg8 and Lys9 of the SNAG domain of Snail 
participate in similar critical contacts within the catalytic cavity of LSD1, compared with 
those of the histone H3 tail. This is consistent with the finding that these mutants lose 
their interaction with LSD1 and their suppressive function on the E-cadherin promoter. 
As methylation of arginine and lysine residues has been reported on other non-histone 
proteins 177, and because Arg3, Arg8 and Lys9 in the SNAG domain of Snail are critical 
for the interaction with LSD1, we speculate that methylation of these three residues may 
regulate their interaction with LSD1. To test this idea, we immunoprecipitated Snail 
protein and performed western blot analysis using antibodies against H3K4, H3K9 and 
H3K27 methylation, as well as antibodies against pan-lysine and pan-arginine 
methylation. Unfortunately, we were unable to detect the methylation of Snail because of 
the lack of a specific methylation antibody on these three residues. Together, our results 
indicate that the SNAG domain of Snail interacts with LSD1 by adopting a conformation 
similar to that of the N-terminal tail of histone H3. 
The amine oxidase domain of LSD1 is responsible for its interaction with Snail 
 The N-terminal one-third of LSD1 contains a SWIRM (Swi3p, Rsc8p and Moira) 
domain that is commonly found in chromatin-remodeling complexes with unknown 
functions (Figure 2.5A). The C-terminal two-thirds of LSD1 comprise an amine oxidase 
(AO) domain that shares extensive sequence homology with FAD-dependent AO. To 
identify the region that is responsible for the LSD1 interaction with Snail, we generated 
LSD1 domain-deletion mutants (Figure 2.5A) and co-expressed them with Snail in 
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HEK293 cells. As expected, immunoprecipitation of full-length LSD1 revealed the 
association with Snail. A small C-terminal deletion mutant of LSD1 and the AO domain 
retained the ability to interact with Snail (lanes 2 and 4; Figure 2.5B). The N-terminal 
region of the SWIRM domain, however, was completely incapable of interacting with 
Snail (lane 3; Figure 2.5B). In the reciprocal immunoprecipitation experiment, 
immunoprecipitation of Snail revealed the associations between full-length and small C-
terminal-deleted LSD1 and the AO domain, but not with the SWIRM domain (Figure 
2.5C). The input lysates of Figure 2.5B and 2.5C were shown in Figure 2.5D. These 
results indicate that the AO domain is required for the interaction of LSD1 with Snail. 
Consistent with this result, when wild-type and deletion mutants of glutathione-S-
transferase (GST)–LSD1 were pulled down from cell lysates, the SWIRM domain of 
LSD1 failed to interact with Snail (lane 3; Figure 2.5E), confirming that the AO domain 
but not the SWIRM domain is required for mediating the interaction of LSD1 with Snail. 
 Although the AO domain of LSD1 shares high sequence homology with other FAD-
containing AOs, it contains a unique 100-amino-acid insertion that forms a tower-like 
structure (tower domain) protruding away from the AO domain (yellow insertion; Figure 
2.5A) 167,175,178,179. The tower domain divides the AO domain of LSD1 into two 
functional lobes, the FAD-binding lobe and the substrate-binding and -recognition lobe. 
CoREST binds to the tower domain and allosterically modulates the interaction of the 
FAD-binding lobe with the substrate-binding lobe of LSD1 and thus controls the 
demethylase activity of LSD1 167,175,178,179. To further narrow down the region that is 
required for the association of the AO domain with Snail, we generated a tower domain-
only LSD1 and a tower-deleted AO domain (AOΔTower) by linking FAD- and substrate-
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binding lobes with a polyglycine linker as described previously (Figure 2.5A) 179. When 
these deletion mutants were co-expressed with Snail in HEK293 cells, the AO and 
AOΔTower mutants were still able to interact with Snail (Figure 2.5F), whereas the tower 
domain failed to interact with Snail. Conversely, immunoprecipitation of AO and 
AOΔTower, but not of the Tower domain, revealed the association of Snail. These results 
indicate that the AO domain, but not the tower region of LSD1, is responsible for the 
interaction of LSD1 with Snail. 
 On the basis of the structural analysis of LSD1, aspartic acid 375 and glutamic acid 
379 form a charge interaction with arginine 8 of histone H3, whereas glutamic acids at 
positions 553, 555 and 556 interact with arginine 2 of histone H3 (Figure 2.5G). Mutation 
of these critical residues within the catalytic domain of LSD1 abolished its catalytic 
activity on H3K4 demethylation. Interestingly, mutation of these residues completely 
compromised the interaction of LSD1 with Snail (Figure 2.5H). Taken together, our data 
indicate that the SNAG domain of Snail adopts a structural conformation similar to that 
of the histone H3 tail and interacts with the catalytic domain of LSD1 in a manner similar 
to that of histone H3. 
CoREST enhances the interaction of LSD1 with Snail and the stability of the 
ternary complex 
 The tower region of LSD1 is required for its interaction with CoREST 167,175,178,179, a 
SANT domain-containing co-repressor. Binding of CoREST not only protects LSD1 
from proteasomal degradation in vivo but also modulates the structure of the AO domain 
of LSD1 to control the interaction of LSD1 with its substrate, histone H3 159,166. Since the 
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sequence of the SNAG domain is similar to that of the N-terminus of histone H3, and the 
SNAG domain of Snail interacts with the AO domain of LSD1, we reasoned that the 
association of CoREST with LSD1 may affect the binding and stability of Snail. To test 
this idea, we expressed Snail, LSD1 or CoREST in HEK293 cells. Consistent with 
previous findings 123,159, treatment with the proteasome inhibitor MG132 significantly 
stabilized Snail and LSD1 (lanes 1 and 2 versus lanes 7 and 8, Figure 2.6A). Co-
expression of Snail with wild-type LSD1, ΔTower LSD1 or CoREST did not change the 
stability of Snail (lanes 2, 3 and 4, Figure 2.6A). As expected, CoREST enhanced the 
stability of wild-type LSD1 but not of ΔTower LSD1 (lane 5 versus lane 6, Figure 2.6A). 
Noticeably, expression of Snail, LSD1 and CoREST together significantly enhanced the 
protein stability of each in the complex, as much as treatment with proteasome inhibitor 
MG132 (lane 5 versus lane 11, Figure 2.6A). These results indicate that the formation of 
the Snail–LSD1–CoREST ternary complex is critical for their protein stabilization and 
function in vivo. Consistent with this finding, when LSD1 was immunoprecipitated, co-
expression of CoREST significantly enhanced the association of LSD1 with Snail (lane 2 
versus lane 1, Figure 2.6B; the input lysates were shown in Figure 2.6C). However, 
ΔTower LSD1, which does not interact with CoREST, could not enhance the interaction 
with Snail in the presence of CoREST (lane 3 versus lane 4, Figure 2.6B). These results 
suggest that the binding of CoREST with the tower domain of LSD1 modulated the AO 
structure of LSD1, and thus enhanced the interaction of LSD1 with Snail. To further 
confirm our finding, we knocked down the expression of endogenous CoREST in 
HCT116, PC3 and MDA-MB231 cells, which slightly decreased the levels of 
endogenous LSD1 and Snail in these cells (Figure 2.6D). Again, when equal amounts of 
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LSD1 were immunoprecipitated (top panel, Figure 2.6E), knockdown of CoREST 
expression significantly decreased the interaction of LSD1 with Snail in these cell lines 
(Figure 2.6E). As LSD1 resides mainly in the nucleus and Snail is localized in the 
nucleus when it is stabilized 123, we measured the expression of Snail, LSD1 and 
CoREST in nuclear extracts from 11 different cancer cell lines. We found that the level of 
Snail was highly correlated with the levels of LSD1 and CoREST in these cells (Figure 
2.6F). Together, our data indicate that the association of Snail, LSD1 and CoREST is 
important for their stability as a functional complex; the binding of CoREST with LSD1 
is not only critical for the stability of LSD1 but also modulates the association of LSD1 
with Snail. 
Interaction with Snail is required for LSD1 recruitment to the E-cadherin promoter 
in vivo 
 We found that the SNAG domain of Snail and the AO domain of LSD1 were required 
for their association, and this interaction was regulated by CoREST. Given a high 
sequence similarity between the SNAG domain and the N-terminus of histone H3, we 
reasoned that Snail used its SNAG domain as a pseudo-substrate for LSD1 by mimicking 
the structure of the histone H3 tail, which allowed for the recruitment of LSD1 to its 
targeted gene promoter. To test this idea, we immunoprecipitated endogenous LSD1 from 
HEK293 (with exogenously expressed Snail), HCT116 and MDA-MB231 cells in the 
presence or absence of Parnate (tranylcypromine), a mechanism-based inhibitor that 
binds to the catalytic cavity of LSD1 180,181. We found that Parnate significantly disrupted 
the interaction of LSD1 with Snail (Figure 2.7A). This inhibitory effect is specific, as 
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Parnate did not alter the association of LSD1 with CoREST. A similar finding was also 
obtained using another LSD1 inhibitor, Pargyline 182. To further extend our observation, 
we added H3K4me0 (1–21 amino acids), H3K4me2 (1–21 amino acids) and SNAG (1–
17 amino acids) peptides for competition binding during the immunoprecipitation of 
endogenous LSD1 in HCT116 and MDA-MB231 cells (Figure 2.7B). We found that H3 
peptides significantly disrupted the interaction of LSD1 with Snail. Noticeably, the 
SNAG peptide completely abolished the interaction of LSD1 with Snail, suggesting that 
the SNAG peptide has higher affinity for binding to LSD1 than does the histone H3 
peptide. Together, these results indicate that agents (inhibitors, histone H3 and SNAG 
peptides) competing for the binding of the catalytic cavity of LSD1 can disrupt the 
association of LSD1 with Snail. 
 To test whether the Snail complex contains LSD1 demethylase activity, we 
immunoprecipitated Snail and incubated the complex with purified mononucleosomes. 
We found that the Snail complex was able to demethylate H3K4me2 in vitro and that this 
enzymatic activity was suppressed by LSD1 inhibitors Parnate and Pargyline (Figure 
2.7C). To further examine whether the Snail–LSD1 complex is associated with the E-
cadherin promoter and mediates transcriptional repression during EMT in vivo, we 
performed chromatin immunoprecipitation (ChIP) assays on two cancer cell lines. As 
expected, Snail and LSD1 can interact with the E-cadherin promoter in these two cell 
lines (Figure 2.7D). Interestingly, the interaction of LSD1 with the E-cadherin promoter 
was significantly decreased when Snail was specifically knocked down in HCT116 cells 
(lane 7 versus lane 8, Figure 2.7E), indicating that the interaction of LSD1 with the E-
cadherin promoter is mediated through the association of Snail that binds to the E-box on 
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the E-cadherin promoter through zinc-finger motifs. Consistent with this idea, no H3K4 
methylation on the E-cadherin promoter could be detected in HCT116 cells (lane 5, 
Figure 2.7E). However, knockdown of Snail or LSD1 expression enhanced the 
methylation of H3K4 (lanes 6, 7 and 8, Figure 2.7F). Taken together, our results indicate 
that the interaction with LSD1 is critical for the suppressive activity of Snail and that 
Snail is required for LSD1 recruitment to the E-cadherin promoter in vivo. 
Knockdown of Snail and LSD1 expression suppresses cell migration 
 To examine the functional relationship of Snail and LSD1 in vivo, we expressed an E-
cadherin promoter luciferase construct in MCF7 cells that expresses no detectable 
endogenous Snail. As expected, co-expression of Snail suppressed E-cadherin promoter 
luciferase activity (Figure 2.8A). However, knockdown of LSD1 expression blocked the 
suppressive effect of Snail on the E-cadherin promoter in these cells. We also measured 
the cell migration of isogenic MCF7 and Snail/MCF cells (Figure 2.8B). As we have 
shown previously, stable expression of Snail in MCF7 cells enhances the migratory 
ability of these cells 103. However, knockdown of LSD1 expression abolished the 
enhancement of Snail-mediated cell migration in Snail/MCF7 cells (Figure 2.8B), 
whereas knockdown of LSD1 expression in MCF7 cells has no significant effect on cell 
migration. These results suggest that the repressive function of Snail depends on LSD1. 
Similarly, we knocked down the expression of Snail or LSD1 or CoREST in HCT116, 
PC3 and MDA-MB231 cells, which express different levels of endogenous Snail, LSD1 
and CoREST, and measured E-cadherin promoter luciferase activity. Knockdown of 
CoREST expression partially derepressed suppression of the E-cadherin promoter. 
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Knockdown of either Snail or LSD1 expression significantly derepressed the suppression 
of the E-cadherin promoter (Figure 2.8C). Knockdown of both Snail and LSD1 
expression further enhanced the activity of the E-cadherin promoter luciferase in all three 
cell lines tested, suggesting that the functional interaction of Snail and LSD1 is important 
for E-cadherin promoter suppression. Consistent with this finding, knockdown expression 
of Snail or LSD1 suppressed the migration of HCT116, PC3 and MDA-MB231 cells, and 
knockdown of both molecules further enhanced this suppressive effect on migration 
(Figure 2.8D). Furthermore, knockdown of Snail, LSD1, CoREST or both Snail and 
LSD1 in PC3 and MDA-MB231 cells impaired the invasiveness of these cells (Figure 
2.8E). In line with these functional changes, knockdown of either Snail or LSD1 
expression decreased the expression of the mesenchymal markers N-cadherin and 
vimentin and enhanced the expression of the tight-junction molecule ZO-1 (Figure 2.8F). 
Knockdown of both molecules can significantly enhance this effect. We speculate that 
this additive effect was due to the higher knockdown efficiency on the functional Snail–
LSD1 repressor complex when both molecules were targeted at the same time. Together, 
our results indicate that the functional interaction of Snail with LSD1 is critical in 
mediating E-cadherin promoter suppression and enhancing cell migration. 
Expression of Snail correlates with the level of LSD1 and CoREST in tumor tissues 
 Having established that the interaction of Snail and LSD1 is critical for their stability 
and for the suppressive function of Snail, we further extended our findings in vivo by 
examining the correlation between the expression of Snail and LSD1 in 116 resected 
human breast tumor specimens. In agreement with previous findings 33, expression of 
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LSD1 was significantly correlated with the expression of CoREST. Again, consistent 
with our results obtained from cell lines, the expression of Snail was highly correlated 
with the expression of LSD1 and CoREST in tumor samples (Figure 2.9A and B). These 
results in human breast cancer tissues confirm our observations in cell culture, lending 
further support to our hypothesis that the interaction of Snail with LSD1 is required for 
their stability and for the suppressive function of Snail during cell invasion and 
metastasis. 
2-4 Discussion 
 In this study, we showed that the interaction of Snail with LSD1 is critical for their 
stability and for the transcriptional repressive function of Snail. Our study provides 
several new insights into the regulation of EMT and metastasis. First, Snail may represent 
the first unique example of a transcription factor that uses a histone-mimicking motif, 
SNAG domain in this case, for recruiting chromatin-modifying enzymes. Although 
transcription factors contain DNA-binding motifs, they do not modify chromatin. In 
contrast, chromatin-modifying enzymes contain many histone-binding modules (such as 
the Bromo, Chromo and PhD domains) and are capable of changing the chromatin 
structure through acetylation or methylation, although they lack specific DNA-binding 
motifs. The manner in which transcription factors recruit specific chromatin-modifying 
enzymes to their target gene promoters remains a subject of major interest and an area of 
intensive investigation. We found that the SNAG domain is required and sufficient for 
Snail to interact with LSD1. Interestingly, the sequence of the SNAG domain is highly 
similar to that of the N-terminus of histone H3 and adopts a conformation similar to that 
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of histone H3 at the catalytic cavity of LSD1. Mutation of the critical contact residues 
(Arg3, Arg8 and Lys9) of the SNAG domain of Snail completely disrupts the interaction 
of Snail with LSD1 and blocks its suppressive activity on the E-cadherin promoter. We 
also found that the SNAG domain of Snail interacts with the AO domain of LSD1, which 
consists of the catalytic core of LSD1 and is required to interact with the tail of histone 
H3 for H3K4 demethylation 167,175,178,179. The interaction of Snail with LSD1 is disrupted 
by LSD1 enzymatic inhibitors and histone H3 peptides. In addition, the Snail–LSD1 
interaction is regulated by CoREST, which is known to bind to the tower region and 
modulates the structure of the AO domain of LSD1 for controlling its interaction with the 
histone H3 tail 167,175,178,179. We showed that expression of CoREST enhanced the 
formation of the Snail–LSD1–CoREST ternary complex and significantly stabilized 
individual components of the complex, whereas knockdown of CoREST expression 
decreased the interaction of LSD1 with Snail. This result is further supported by the 
finding that expressions of Snail, LSD1 and CoREST are highly correlated in multiple 
cancer cell lines and in the 116 primary breast cancer samples. The region connecting the 
SNAG domain and the zinc-fingers in Snail contains a serine-rich motif. We, along with 
others, previously showed that this serine-rich motif is highly phosphorylated and 
controls the subcellular localization and stability of Snail 123,173,174. As Snail is a labile 
protein, we speculate that deletion or mutation of the SNAG domain disrupts the 
interaction of Snail with the LSD1–CoREST complex, and thus leads to the accessibility 
of phosphorylation and consequent proteasome degradation by GSK-3β and β-Trcp 
123,173,174. This is supported by the finding that the SNAG domain does not alter 
subcellular localization but controls the stability of Snail. Our results also indicate that 
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the association of LSD1 with the E-cadherin promoter requires the binding of Snail. 
Knockdown of Snail expression inhibits the association of LSD1 with the E-cadherin 
promoter. Our results, together with previous findings, lead us to propose a plausible 
model for how Snail recruits the LSD1–CoREST complex to its targeted gene promoter 
for transcriptional repression (Figure 2.9C). The SNAG domain of Snail resembles a 
histone H3-like structure and functions as a molecular ‘hook' (or pseudo-substrate) to 
interact with LSD1–CoREST. The formation of this ternary complex stabilizes the 
individual components from potential proteasome degradation. Snail brings this complex 
to its targeted gene chromatin through the binding of the E-box through zinc-finger 
motifs. An overabundant amount of histone H3 at the chromatin region outcompetes the 
binding of the SNAG domain with the catalytic core of LSD1 and results in the 
demethylation of histone H3K4. Our study is supported by the finding that the SNAG 
domain of GFI1 interacts with LSD1 and CoREST and that this interaction is required for 
hematopoietic cell differentiation 163. Although our model provides a new mechanism for 
the manner in which Snail recruits chromatin-modifying enzymes to target gene 
promoters, there are many questions remaining for further investigation. For example, 
future studies should address whether Arg3, Arg8 and Lys9 on the SNAG domain are 
methylated in vivo and how the SNAG domain is released from the LSD1-binding pocket 
after Snail interacts with promoter DNA. Elucidation of these questions will provide new 
insights into the regulation of EMT and metastasis. 
 Second, our study indicates that Snail uses either the SNAG domain or the CtBP-
binding motif for recruiting the LSD1–CoREST complex. All vertebrate Snail genes 
contain the SNAG domain, but they do not have a CtBP-binding motif. However, 
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Drosophila Snail does not contain the SNAG domain, but it has a consensus PxDLSx 
motif that is required to interact with the co-repressor CtBP 93,172,183. Both the SNAG 
domain and the CtBP motif are critical for the function of vertebrate and Drosophila 
Snail, respectively. Deletion or mutation of the SNAG domain abolishes the repressive 
function of SNAG domain-containing transcriptional repressors 184-186. Similarly, 
mutation or deletion of the CtBP-binding motif in Drosophila Snail eliminates its 
repressive activity 187. Interestingly, LSD1 was initially identified as a protein associated 
with CtBP1 during protein purification and it has been confirmed that the interaction of 
LSD1 and CtBP1 is critical for many repressor complexes 170. Thus, our results suggest 
that vertebrate and Drosophila Snail recruit the same LSD1–CoREST co-repressor 
complex for their repressive function through either the SNAG domain or the CtBP-
binding motif. 
 Third, our study confirmed that Snail uses different co-repressor complexes to 
achieve its repressor function during the EMT process. The reciprocal relationship of 
H3K4 and H3K27 methylation in gene regulation is exemplified by the antagonistic 
action of TrxG and PcG proteins 188,189. In our study, Snail interacted with the LSD1–
CoREST complex, resulting in demethylation of H3K4me2 at the E-cadherin promoter to 
suppress its expression. Interestingly, Snail has been shown to interact with EZH2 and 
Suz12 of PRC2 and induce the trimethylation of H3K27 at the E-cadherin promoter 152.   
The specific mechanism of how the Snail-mediated demethylation of H3K4 and 
methylation of H3K27 cooperate to repress E-cadherin requires further investigation. The 
findings that Snail also interacts with PRMT5 154 and the Sin3A–HDAC1/2 complex 147  
adds another layer of intricacy to the regulation of E-cadherin expression during EMT. In 
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Drosophila, transcriptional silencing is initiated through the removal of H3K4 
methylation by the LSD1 homologue SU(VAR)3-3 190, indicating that the demethylation 
of H3K4 by LSD1 is the critical initiating step for gene silencing. However, E-cadherin is 
frequently silenced through DNA hypermethylation on its promoter in many cancer cell 
lines and tumor samples 191. The manner in which the demethylation of H3K4 by the 
LSD1–CoREST complex cooperates with H3K27 trimethylation and H3/H4 
deacetylation, and subsequently leads to E-cadherin promoter methylation remains an 
important area for further investigation. 
 In summary, we demonstrated that the interaction with the LSD1–CoREST complex 
is critical for the stability and function of Snail. Our results provide a new model for how 
a transcription factor recruits chromatin-modifying enzymes to target gene promoter 
during transcription. This finding has important clinical ramifications in that chemical 
compounds that mimic the structure of the SNAG domain of Snail may hold great 
promise for inhibiting the function of Snail in mediating EMT induction and cancer 
metastasis. 
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Figure 2.1 Snail interacts with LSD1 through the SNAG domain.  
(A) The schematic diagram shows the stable expression of dual-tagged Snail in HEK293 
cells (top and middle panels). The Snail complex was isolated by two-step 
immunopurification, separated on SDS–PAGE and visualized by silver staining. A 
protein with molecular weight close to 110 kDa was excised and identified as LSD1 by 
mass spectrometry (bottom panel). (B) Flag-tagged LSD1 and HA-tagged wild-type or 
SNAG-deleted Snail were co-expressed in HEK293 cells. After immunoprecipitation, 
bound Snail or LSD1 was examined by western blotting. (C) Endogenous Snail and 
LSD1 were immunoprecipitated from PC3, HCT116, SKBR3 and MDA-MB231 cells 
and bound endogenous LSD1 and Snail were examined by western blotting. (D) GFP-
tagged Snail was expressed in HEK293 cells. After fixation, the cellular localization of 
Snail (green) and LSD1 (red) was examined by immunofluorescent staining. Scale bar = 
50 µm. 
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Figure 2.2 The SNAG domain is essential for the stability of Snail.  
(A) Sequence alignment of the SNAG domain from several transcriptional repressors. 
The consensus sequence is shown in red and the lysine and arginine residues are 
highlighted in blue. (B) Scheme showing the SNAG constructs used in this study (top 
panel). WT or SNAG-deleted Snail, d2-GFP or SNAG-d2-GFP was co-expressed with 
the E-cadherin promoter luciferase construct in MCF7 cells. After 48 h, luciferase 
activity was measured by using a Dual-Luciferase Reporter Assay (Promega) (mean ± 
s.d. of three separate experiments; bottom panel). (C) Vector, WT- or ΔSNAG-Snail were 
co-expressed with the E-cadherin promoter luciferase construct in MCF7 cells. After 42 
hr, cells were treated with MG132 for 6 hours and luciferase activity was measured using 
the Dual-Luciferase Reporter Assay (Promega) (mean ± SD of three separate 
experiments) (bottom panel). (D) WT and SNAG-deleted Snail, d2-GFP and SNAG–d2-
GFP were expressed in HEK293 cells and analyzed by western blotting. (E) WT or 
SNAG-deleted Snail was expressed in HEK293 cells then treated with cycloheximide (10 
µg/ml) for different time intervals. The level of Snail was analyzed by western blotting. 
Densitometry results from three independent experiments were statistically analyzed and 
plotted (bottom panel). A representative western blotting experiment is shown in the top 
panel. (F) d2-GFP or SNAG-fused d2-GFP was expressed in HEK293 cells and treated 
with cycloheximide as described above. The level of d2-GFP was analyzed by western 
blotting. Densitometry results from three independent experiments were statistically 
analyzed and plotted (bottom panel) and a representative blot is shown on the top panel. 
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Figure 2.3 The SNAG domain does not control the subcellular localization of Snail. 
(A) d2-GFP or SNAG-d2-GFP was expressed in HEK293 cells. The subcellular 
localization of d2-GFP (green) was visualized by immunofluorescence microscopy (Dapi 
for nuclei, red) and assessed in 200 cells at 4 different views. The bar graph shows the 
percentages of cells with the indicated subcellular localization. (B) EGFP-tagged WT or 
SNAG-deleted Snail was expressed in HEK293 cells. The subcellular localization of 
Snail (green) was visualized by immunofluorescence microscopy (Dapi for nuclei, red) 
and assessed as described above. (C) d2-GFP or SNAG-d2-GFP and WT or SNAG-
deleted Snail was expressed in HeLa cells. The subcellular localization of d2-GFP (top 
panel) and Snail (bottom panel) were analyzed by cellular fractionation. Tubulin and 
poly-adenosine ribose polymerase (PARP) were used as markers of the cytoplasmic and 
nuclear fractions, respectively. 
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Figure 2.4 The SNAG domain of Snail interacts with LSD1 by mimicking the structure 
of the tail of histone H3.  
(A) d2-GFP or SNAG–d2-GFP was expressed in HEK293 cells. After 
immunoprecipitation of d2-GFP, bound endogenous LSD1 was examined by western 
blotting. (B) The schematic diagram shows the sequence alignment of the SNAG domain 
with the histone H3 tail. The conserved sequence is highlighted in yellow and arginine 
and lysine resides are shown in red. Residues of Arg2, Thr6, Arg8, Lys9 and Thr11 of 
histone H3 (highlighted in blue dots on the top) are important for establishing the critical 
interaction of histone H3 within the catalytic cavity of LSD1. Triangles at the bottom 
represent the residues on the SNAG domain that are important for interacting with LSD1. 
(C) Schematic diagram shows the position of the alanine mutations in the SNAG domain 
(top panel). The Snail mutants were expressed in HEK293 cells and the level of Snail was 
examined by western blotting (bottom panel). (D) EGFP-tagged WT or mutant Snail was 
expressed in HEK293 cells and the subcellular localization of Snail (green) was 
visualized by immunofluorescence microscopy (DAPI for nuclei, red). Scale bar = 20 
µm. (E) WT or mutant Snail was expressed in HEK293 cells treated with MG132 (10 
µM) for 6 h. Endogenous LSD1, WT or Snail mutants were immunoprecipitated, and the 
bound Snail or endogenous LSD1 was examined by western blotting, respectively. Input 
lysates were shown in the bottom panel. (F) Vector, WT or SNAG-domain mutants of 
Snail were co-expressed with the E-cadherin promoter luciferase construct in MCF7 
cells. After 48 hr, luciferase activity was measured using a Dual-Luciferase Reporter 
Assay (Promega) (mean ± SD of three separate experiments). (G) A ball-and-stick model 
structure of the LSD1–SNAG–Snail complex (green) superposed to the LSD1–histone 
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H3 peptide complex (yellow; PDB access code 2V1d) showing the position of key 
interacting residues and the substrate lysine residue (Lys4). The LSD1 molecule is shown 
as a partially transparent surface representation. 
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Figure 2.5 AO domain of LSD1 is responsible for its interaction with Snail.  
(A) The cartoon and schematic diagram shows the structure of LSD1 and the different 
deletion constructs used in this study. (B, C) HA-tagged Snail and Flag-tagged full-length 
or deletion mutants of LSD1 were co-expressed in HEK293 cells treated with MG132 for 
6 h. After immunoprecipitation, bound Snail (B) and LSD1 (C) were examined by 
western blotting. (D) Lysates of (B) and (C) were analyzed for the expression of different 
deletion mutants of LSD1 and Snail by Western blotting. (E) GST-tagged full-length or 
deletion mutants of LSD1 were incubated with lysate from HEK293 cells expressing 
Snail. The GST pull-down complex was eluted with SDS–PAGE buffer and about one-
tenth of these elutents were analyzed for the association of Snail by western blotting 
(bottom panel). The rest of the elutents were examined for the presence of purified GST–
LSD1 by Coomassie staining (top panel). (F) Flag-tagged AO domain, AO domain 
without Tower (AOΔTower) or Tower domain of LSD1 was co-expressed with Snail in 
HEK293 cells treated with MG132 for 6 h. After immunoprecipitation, the bound 
deletion mutants of LSD1 and Snail were examined by western blotting. (G) The 
schematic diagram shows the positions of D375, E379, D553, D555 and D556 that 
interact with the arginine 8 (R8) and arginine 2 (R2) of histone H3, respectively. (H) 
Flag-tagged wild-type or mutant LSD1 were co-expressed with HA-tagged Snail in 
HEK293 cells. After immunoprecipitation of LSD1 and Snail, the bound Snail and LSD1 
were analyzed by Western blotting, respectively. 
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Figure 2.6 CoREST enhances the interaction of LSD1 with Snail and the stability of the 
ternary complex.  
(A) Snail, WT or Tower-deleted LSD1, and CoREST were co-expressed in HEK293 
cells. Cells were treated with or without MG132 for 6 h before being collected. The 
levels of LSD1, Snail and CoREST were analyzed by western blotting. (B) WT or 
Tower-deleted LSD1 and CoREST were co-expressed in Snail/HEK293 cells. After 
immunoprecipitation of LSD1, the bound Snail and CoREST were examined by western 
blotting. (C) Lysates of (B) were analyzed for the expression of LSD1, CoREST and 
Snail by Western blotting. (D) CoREST siRNA or non-target control (NTC) was 
expressed in HCT116, PC3 and MDA-MB231 cells. Endogenous LSD1, CoREST and 
Snail were examined by western blotting. (E) Cells were prepared as described above in 
(D). After endogenous LSD1 was immunoprecipitated, the bound CoREST and Snail 
were examined by western blotting. (F) Nuclear extracts from various cancer cell lines 
were analyzed for the levels of Snail, LSD1 and CoREST by western blotting. Lamin A 
served as the nuclear marker. The expression intensity of these proteins was plotted and 
shown (bottom panel). 
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Figure 2.7 Interaction with Snail is required for LSD1 recruitment to the E-cadherin 
promoter in vivo.  
(A) The LSD1 enzymatic inhibitor Parnate (100 µM) was added to the 
immunoprecipitation buffer during immunoprecipitation. After endogenous LSD1 was 
immunoprecipitated from HEK293 (expressing exogenous Snail), MDA-MB231 and 
HCT 116 cells, bound Snail and CoREST were detected by western blotting. (B) 
H3K4me0 (1–21 amino acids), H3K4me2 (1–21 amino acids) and SNAG peptides (60 
µg/ml) were added to the immunoprecipitation buffer during immunoprecipitation. After 
endogenous LSD1 was immunoprecipitated, bound Snail and CoREST were detected by 
western blotting as described above. (C) In vitro histone demethylation assay was carried 
out as described in the Materials and methods section using mononucleosomes as 
substrate. After the reaction, demethylation of histone H3K4 was examined by western 
blotting. The statistical analysis for the demethylation from three independent 
experiments is shown on the bar graph (top panel). A representative demethylation assay 
is shown in the bottom panel. (D) The association of endogenous Snail and LSD1 with 
the E-cadherin promoter was analyzed by chromatin immunoprecipitation (ChIP) assay in 
HCT116 and BT549 cells. (E) Snail, LSD1 or non-target control (NTC) siRNA was 
expressed in HCT116 cells, the association of endogenous Snail and LSD1 with the E-
cadherin promoter was analyzed by ChIP assay. (F) Snail, LSD1 or non-target control 
siRNA was expressed in HCT116 cells; methylation of H3K4 on the E-cadherin promoter 
was analyzed by CHIP assay using anti-H3K4me2 antibody. 
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Figure 2.8 Knockdown of Snail and LSD1 expression suppresses cell migration.  
(A) An E-cadherin promoter luciferase construct was co-expressed with or without Snail, 
non-target control (NTC) or LSD1 siRNA in MCF7 cells. After 48 h, luciferase activities 
were normalized and determined (mean ± s.d. of three separate experiments). Luciferase 
activities for each sample were statistically analyzed by Student’s t-test (P < 0.01). *, P < 
0.001; #, no significance. (B) LSD1 or NTC siRNA was expressed in isogenic MCF7 and 
Snail/MCF7 cells. After 48 h, a scratch (‘wound’) was induced in a cell monolayer and 
cell culture was continued for an additional 48 h. Images were obtained at the beginning 
and at the 48 h time point to monitor the cell migration for the closure of the wound. The 
percentage of cell migration was calculated on the basis of the migration of MCF7 cells 
(experiments were conducted at least twice in duplicate). Statistical analysis was 
performed by Student’s t test (P < 0.01). *, P < 0.001; #, no significance. (C) Snail (SN), 
LSD1, CoREST and NTC siRNA were co-expressed with the E-cadherin promoter 
luciferase construct in HCT116, PC3 and MDA-MB231 cells. After 48 h, luciferase 
activities were normalized and determined. (D) Snail (SN), LSD1 and NTC siRNA were 
expressed in HCT116, PC3 and MDA-MB231 cells as described in (C). After 48 h, a 
scratch (‘wound’) was induced in a cell monolayer and cell culture was continued for 48 
h to measure cell migration as described in (B). The migration of PC3 cells is shown on 
the bar graph. (E) The invasive ability of PC3 and MDA-MB231 cells was analyzed by 
the invasion assay. Invaded cells from 6 different view areas were counted and plotted as 
bar graph (mean ± SEM of three separate experiments). (F) PC3 cells were treated as 
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described above and expressions of LSD1, Snail, N-cadherin, vimentin, ZO-1 and Actin 
were examined by western blotting. 
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Figure 2.9 Expression of Snail correlates with the level of LSD1 and CoREST in tumor 
tissues.  
(A) The 116 surgical specimens of breast cancer were immunostained using antibodies 
against Snail, LSD1, CoREST, and the control serum (data not shown). Representative 
stainings from the same tumor samples are shown. Scale bar = 100 µm. (B) The 
expression patterns of Snail, LSD1 and CoREST in the 116 breast tumor samples were 
determined and summarized. Correlation of Snail with LSD1 and CoREST was analyzed 
using Fisher’s exact test (P < 0.001). P < 0.05 was set as the criterion for statistical 
significance. (C) A proposed model to illustrate how Snail recruits the LSD1-CoREST 
complex to the E-cadherin promoter. The SNAG domain of Snail assembles a histone 
H3-like structure and serves as a molecular ‘hook’ (or pseudo substrate, a red dot 
indicates the critical residues in Snail and histone H3 that interact with LSD1) to interact 
with the LSD1–CoRESTcomplex. The formation of this complex stabilizes the individual 
components from potential proteasomal degradation. Snail brings this complex to its 
targeted gene promoters through the binding of the E-box through the zinc-finger motifs. 
An overabundant amount of histone H3 at the chromatin region outcompetes the binding 
of the SNAG domain with the catalytic core of LSD1 and results in the demethylation of 
histone H3K4. 
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Chapter 3: Histone mimics: digging down under  
3-1 Introduction 
 As early as two decades ago, Arents and colleagues identified a common motif shared 
by four core histones when they performed crystallographic analysis to determine the 
structure of the histone octamer 192. They found that individual polypeptides in the central 
portion of histone chains are folded in a similar manner and named this helix-loop-helix 
motif the histone fold 192. Driven by previous findings that a couple of proteins such as 
TAFII40 and TAFII60 from Drosophila and macro-H2A from rat also contain histone-like 
components, Arents and colleagues reasoned that histone fold might also be prevalent in 
certain groups of nonhistone proteins. They performed computer-based motif searches 
and sequence analysis, and indeed confirmed the presence of the histone fold in a number 
of nonhistone proteins, most of which are involved in protein-protein or protein-DNA 
interactions 193. These proteins, which include transcription factors and enzymes, were 
defined to form a distinct histone fold superfamily 194. Further research by Arents and 
colleagues demonstrated that the histone fold plays a role in DNA compaction and 
protein dimerization 194. The histone fold superfamily represents the earliest example of 
histones and nonhistone proteins sharing a common motif. It should be noted, however, 
that when a certain group of proteins share a common histone-like structure or sequence, 
they might appear to have quite different functions. At that time, the biological 
significance of “histone mimicking” remains unclear.  
 Recently, Sampath and colleagues addressed some of these questions by providing a 
typical example in the name of G9a, which belongs to the Suv(3-9) family of SET 
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domain histone methyltransferases and possesses histone H3 lysine 9 methylation 
abilities 195. Through sequence alignment, they identified a short conserved sequence 
within the N-terminal of G9a as well as its family member GLP (G9a-like protein). 
Interestingly, they found that the sequence highly resembled the histone H3K9 
methylation site. They continued to confirm that G9a was subject to auto-methylation at 
lysine 165 within the conserved sequence; and the auto-methylation was required for G9a 
to form corepressor complex with HP1γ, the euchromatic isoform of HP1 which was 
previously found to recognize methylated lysines at the histone H3 tail through its 
prototypical chromodomain. Nuclear magnetic resonance (NMR) spectroscopy analysis 
further defined that HP1γ binds methylated G9a with similar manner to that of HP1γ-
methyl-H3K9.  
 In our recent study, we demonstrated that the SNAG domain of Snail functions as a 
molecular hook, or “pseudo-substrate”, for recruiting LSD1 to E-cadherin promoter for 
transcription repression 142. The structural similarity between SNAG domain and histone 
H3 tail upon LSD1 binding represents another typical example for histone mimicry. 
Baron and colleagues performed a more detailed structural analysis of SNAG-LSD1 
binding and found that the positively charged groups and hydroxyl side chains shared by 
N-terminal tails of Snail and H3 enable them to fit into the catalytic cavity of LSD1 in a 
similar conformation 196. Based on these results, we hypothesized that the SNAG domain-
mimicking chemical compounds may inhibit Snail-LSD1 association, thus disrupting 
their roles in EMT induction and tumor progression. To test this idea, we synthesized a 
patch of compounds structurally based on the SNAG domain, and screened candidates 
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that may efficiently compete with Snail for LSD1 binding through peptide pulldown 
assays.   
 As mentioned, the Snail-LSD1 interaction provides a unique model of transcription 
factor recruiting chromatin enzymes. Since histone H3 peptide has been shown to 
associate with multiple chromatin enzymes and modulators by adopting different 
conformations 197-201, we hypothesized that in addition to LSD1, the SNAG domain can 
interact with other molecules by mimicking H3 tail and recruit them to its target gene 
promoters. In the second part of our study, we tried to address this hypothesis by 
applying a SNAG peptide pulldown-mass spectrometry-coupled analysis to identify 
SNAG-interacting proteins. Interestingly, among the candidates we identified, many are 
chromatin-associated proteins; while some have been previously reported to form 
complexes with Snail, a few others have not been published before and may represent 
novel targets for studying Snail-mediated epigenetic regulation. 
3-2 Materials and methods 
Peptide and Chemical compounds  
 C-terminal biotinylated peptide was synthesized according to the sequence of the 
SNAG domain of Snail protein. Chemical compounds were designed based on computer 
modeling analysis of the structure of the SNAG domain with various modifications.  
Peptide pulldown 
 Biotin-labeled SNAG peptide was pre-incubated with streptavidin beads. Cell lysate 
was then added to the peptide-beads combo for overnight incubation at 4ºC. The complex 
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was washed extensively with lysis buffer and PBS and resolved by 10% SDS-PAGE. For 
identification of SNAG-associated proteins, the gel was subject to silver staining and the 
protein bands were excised for mass spectrometry analysis. For competition assays, 
chemicals were added at different concentrations during overnight incubation. Parnate 
and DMSO were used as positive and negative control, respectively. After washing and 
SDS-PAGE separation steps, western blot was performed using LSD1 antibody.  
3-3 Results 
Screening of chemical compounds that efficiently disrupt Snail-LSD1 interaction 
 A batch of 54 compounds was initially entered for the screening process. During the 
time of dissertation preparation the screening was still underway. Three chemicals have 
been identified so far to significantly inhibit peptide-LSD1 binding at concentration of 
100 µM (Figure 3.1). These chemicals were further tested at the concentration of 10 µM 
and only one of them retained the inhibitory effect (Figure 3.1). Upon finishing the initial 
screening we hope to identify some lead compounds that are effective at the 
concentration range of 1-5 µM.  
Identification of SNAG-associated proteins  
 To further identify SNAG-associated proteins besides LSD1, we applied peptide 
pulldown-mass spectrometry-coupled analysis as described above. The gel was subject to 
silver staining as shown in Figure 3.2. The protein identified include many chromatin 
enzymes and modulators, such as LSD1, CoREST, BHC80, HDAC1/2, EZH2, KDM5B 
(lysine (K)-specific demethylase 5B, which is an H3K4me3-specific demethylase) and 
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NSD2 (Nuclear receptor-binding SET domain protein 2, which harbors histone lysine 
methyltransferases activity), among others.   
3-4 Discussion 
 This study is a further extension of our previous research demonstrating that the 
SNAG domain of Snail mimics histone H3 tail and functions as a pseudo substrate for 
recruiting histone-modifying enzyme LSD1. For the first part, we are screening a pool of 
SNAG-mimicking chemical compounds for candidates that can efficiently disrupt Snail-
LSD1 interaction. Previously, there have been several studies on histone-mimicking 
drugs. Chang and colleagues reported that adding a lysine mimic to an established G9a 
inhibitor BIX-01294 could enhance its potency in vitro and reduce cell toxicity in vivo 
202. In addition, Nicodeme and colleagues reported that I-BET, a synthetic compound 
mimicking acetylated histones, can bind the bromodomain and extra terminal domain 
(BET) proteins with high affinity, thus disrupting BET protein-mediated assembly of 
chromatin complexes responsible for the expression of key inflammatory genes 203. In 
vivo studies further showed that I-BET treatment conferred protection effect and 
suppressed inflammation in mice 203. While further efforts are still needed for the 
development of ideal small molecule inhibitors in specific pathological circumstances, 
histone mimicry-based compounds do show great promise. As demonstrated in Chapter 
1, Snail and LSD1 cooperate to induce tumor cell migration and invasion, and expression 
of Snail highly correlates with that of LSD1 in multiple human breast tumor tissues. In 
this regard, SNAG-mimicking chemicals that compete with Snail for LSD1 binding 
would hold big potential for inhibiting their roles during metastatic progression of 
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tumors.  
 With the help of Dr. Watt and his colleagues in Department of Biochemistry, 
University of Kentucky, we designed a patch of chemicals through computer modeling 
based on the structure of SNAG as it fits into the catalytic cavity of LSD1. One of our 
considerations during design is the lipid solubility of chemicals which would allow them 
to penetrate the lipid cellular membrane to take effect; on the other hand, since a drug is 
transported in blood and intracellular fluid, it should be sufficiently water-soluble. The 
solubility of a drug is largely determined by its number of hydrogen bond donors vs. 
alkyl sidechains. The partition coefficient, which depicts the ratio of compound 
concentrations in water/lipid at equilibrium, is used to evaluate solubility. Generally, the 
logarithm of the octanol/water partition coefficient, known as Log P, should be in the 
range of -0.4 to +5.6. In addition to solubility, the molecular weight of the compounds 
was taken into consideration, as it also affects the diffusion rate.  
 At the starting stage, we are using peptide pulldown-coupled competition assay to 
screen these compounds. Experimental conditions such as amount of protein input, 
complex incubation time, peptide concentration and washing stringency have been 
optimized. We started to test the chemicals at 100 µM and tried to reduce the 
concentration without significantly compromising the inhibitory effect on peptide-LSD1 
interaction. A couple of “lead compounds” will be determined and further modified for 
the improvement of efficacy. A chemical is considered promising candidate if it retains a 
significant inhibitory effect within nanomole range, which is comparable to that of LSD1 
inhibitor Parnate.  
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 Once promising candidates have been identified, further assays will be used to test 
their biological activities. For example, we plan to perform promoter luciferase assay to 
test if chemicals can derepress E-cadherin promoter by disrupting Snail-LSD1 interaction 
in different tumor cells; cell invasion and migration assays will also be performed to test 
if chemical treatment can compromise these activities of tumor cells. In addition, the 
overall cell growth rate upon compound treatment will be measured by MTT assay to 
evaluate drug toxicity. Overall, these in vitro screenings will provide molecular basis for 
potential in vivo studies in the future to explore the clinical significance of SNAG-
mimicking compounds.   
 For the second part of this study, we applied peptide pulldown-mass spectrometry-
coupled analysis to identify SNAG-interacting proteins. Our study was inspired by the 
“histone code” hypothesis. As stated by Jenuwein and Allis 2, histone tails are subject to 
multiple post-translational modifications, which collectively create a “histone code” to be 
interpreted by the recruitment of other chromatin modulators through specific recognition 
domains. For example, the HAT (histone acetyltransferases) domain has been 
demonstrated to mediate histone acetylation, which can be recognized by proteins 
harboring bromodomains; the SET domain, by contrast, mediates lysine methylation, 
which recruits chromodomain-containing proteins. Other examples include methylated 
arginine-recognizing Tudor domain and methylated lysine-recognizing PHD (Plant 
Homeo Domain) finger. Due to the structural flexibility, histone tails can adopt various 
conformations, which have been illustrated by structural analysis of different chromatin 
protein-H3 peptide complexes 197-201. Considering the histone H3 tail-mimicking property 
of the SNAG domain, we are wondering if SNAG is also subject to multiple 
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modifications and further recognized by different chromatin proteins, which coordinately 
control the transcription of Snail target genes. It is possible, for example, that LSD1 
works with a yet-to-be-identified lysine methyltransferase to define the methylation status 
of the SNAG domain: under specific biological circumstances, one might become tightly 
bound to and modify the SNAG domain while the other goes off, or vice versa. It would 
be tantalizing to characterize this dynamic “switch”, as well as to specify the other 
potential cofactors involved in this regulatory process.  
 Our enthusiasm was further boosted by recent studies of Sampath and colleagues 
demonstrating that the lysine methyltransferase G9a is subject to auto-methylation on its 
histone H3-resembling site, and the auto-methylation is required for binding HP1γ to 
form a corepressor complex 195. Their findings offered us several implications. First, 
there is an overlap between histone and nonhistone modification systems and one of their 
linkages would be the histone-like modification cassettes: the histone mimics. Second, 
the histone code hypothesis might go beyond histone and apply more universally to 
nonhistone proteins. Third, it might be possible to predict nonhistone targets based on 
their structural or sequential similarity to the corresponding histone modification sites. 
Indeed, the initial studies performed by Sampath and colleagues, as well as by others, 
have identified a number of proteins harboring H3K9-mimicking cassettes and therefore 
representing potential targets of G9a. Interestingly, many of these proteins are associated 
with chromatin regulation, including mAM 195, which is a murine ATFa-associated factor 
and stimulates the activity of histone H3K9 methyltransferase ESET; as well as NSD1 
and NSD3 204, which possess histone H3K36 methyltransferase activities. In this regard, 
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extensive sequential and structural analysis will help to predict whether the SNAG 
domain is subject to modification by different chromatin enzymes.   
 Chan and colleagues recently reported an unbiased proteomic screen for histone H3 
peptide-bound proteins 205. Through a sensitive pull-down approach in combination with 
LC-MS/MS analysis, they identified 86 nuclear proteins that associated with histone H3 
peptides harboring different lysine modifications 205. Given the resemblance between the 
histone H3 tail and the SNAG domain, a similar strategy to identify interacting proteins 
of the SNAG peptide with different modifications would be applicable. Currently, 
through a similar approach we identified various proteins interacting with unmodified 
SNAG peptide. Excitingly, many of them are chromatin enzymes and modulators. We 
also sent a peptide-absent pulldown sample for analysis as the negative control. The 
presence of LSD1 and CoREST only in peptide-present pulldown sample confirmed our 
findings as depicted in Chapter 1. Furthermore, identification of new SNAG-interacting 
candidates goes in line with our hypothesis that SNAG plays a critical role in 
coordinating multiple chromatin enzymes and modulators. At this point we cannot 
exclude the possibility that these proteins associate with the SNAG peptide through 
indirect effects (e.g. through interaction with LSD1). A peptide pulldown assay to 
directly capture purified proteins will help to clarify this issue. We are currently 
searching literatures on the newly identified candidates and looking to select promising 
molecules for the continual study of Snail-mediated epigenetic regulation network.  
 As conclusion, in this study we are trying to explore our discovery of SNAG-
mediated LSD1 recruitment by defining SNAG-mimicking compounds for efficient 
disruption of Snail-LSD1 interaction, as well as by identifying and characterizing SNAG-
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interacting proteins besides LSD1. Our study will contribute methodologically and 
theoretically to a better understanding as well as control of Snail-mediated epigenetic 
events during cancer development,  
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Figure 3.1 Peptide pulldown assay to screen compounds that inhibit SNAG-LSD1 
binding. 
Chemical compounds were added at concentrations of 100 µM and 10 µM during SNAG 
peptide pulldown. The peptide-bound LSD1 was detected by western blot. CT, control 
(without chemicals); PAR, Parnate; 1-8, chemical numbers.  
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Figure 3.2 Identification of SNAG peptide-interacting proteins. 
Peptide pulldown samples were separated on SDS-PAGE and subjected to silver staining 
before mass-spectrometry analysis. Peptide-absent sample was used as negative control.  
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Chapter 4:  Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a 
PARP1-dependent manner 
4-1 Introduction 
 Cancer cells distinguish themselves from their normal siblings with the capability of 
evading apoptosis and presenting uncontrolled cell division, along with acquiring 
malignant characteristics such as invasion and metastasis. The conventional 
chemotherapeutic drugs function by introducing DNA damage to impair cell division. 
Since most cancer cells outgrow their normal counterparts, the property of rapid DNA-
replication makes them more vulnerable to the DNA lesions. On the other side, a portion 
of cancer cells have their own defensive strategies, either harboring intrinsic capability to 
escape apoptosis or developing resistance following drug exposure, which allow for 
tumor recurrence and progression. Chemoresistance is determined by aberrant genetic 
settings in combination with diverse epigenetic alterations, reflected by abnormal 
signaling pathways controlling drug accumulation and distribution, cell proliferation, 
DNA repair and apoptosis 206. While great effort has been made to elucidate the 
underlying mechanism, our knowledge of drug resistance is still fragmentary.     
 As mentioned, Snail functions not only as a master regulator of epithelial-
mesenchymal transition (EMT) that promotes tumor metastasis 99,123,171,207,208, but also as 
an important molecule that induces immunosuppression, bestows cancer cells with stem-
like traits, and mediates cancer cell survival 209. Typically, Snail can become stabilized 
and bind to PTEN promoter to repress its transcription during γ radiation-induced 
apoptosis 130. It has also been documented that upon doxorubicin treatment, the pro-
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survival Akt pathway becomes activated to render breast cancer cells resistant to drug-
induced apoptosis 210. Based on the findings that PTEN negatively regulates the 
PI3K/Akt pathway 211, and that overexpression of Akt can induce NF-κB-dependent Snail 
activation 212, there is a plausible positive feedback loop in which Snail boosts its own 
transcription through PTEN suppression. Despite these findings, extra questions remain 
in regard to the mechanistic details of Snail-mediated apoptosis protection, and it is not 
until we comprehensively understand the “fight-back” mechanism can we develop 
efficient strategies to defeat cancer eventually.   
 We recently applied an affinity purification-mass spectrometry coupled analysis to 
identify Snail-interacting proteins, among which are lysine-specific demethylase 1 
(LSD1) and poly(ADP-ribose) polymerase 1 (PARP1) 142. In our study, we demonstrated 
that Snail uses its SNAG domain as a pseudo-substrate to form complex with LSD1 142. 
Furthermore, we found that the expression of Snail was significantly co-related with that 
of LSD1 in multiple human breast cancer tissues 142. Interestingly, according to other 
recent studies, LSD1 can either render tumor cells resistant to DNA damage or reversely 
prompt cells to undergo apoptosis in different biological settings, indicating that LSD1 
plays a role in cell survival 213-216. As mentioned, one of the critical oncogenic roles of 
Snail lies in apoptosis protection notably through transcriptional repression of PTEN, 
which serves as a negative regulator of survival Akt signaling. It would be interesting to 
find out if LSD1 is involved in Snail-mediated PTEN suppression and cell survival.  
 Besides LSD1, PARP1 is another intriguing candidate that serves as a key factor in 
DNA repair and cell survival. PARP1 is the founding member of the PARP family 
consisting of 18 homologues 217. PARP1 becomes immediately activated in response to 
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single-strand DNA breaks, and utilizes NAD+ as substrate to synthesize poly(ADP-
ribose) polymer (pADPr), which functions as a signal for recruiting other DNA-repairing 
enzymes 218,219. If not repaired, single-strand DNA breaks will cause the replication fork 
to stall and double-strand DNA breaks to accumulate during DNA replication 220. Since 
many breast cancers have defects in BRCA1/BRCA2-mediated homologous 
recombination (HR) repair pathway that deals with double-strand breaks, they would rely 
on PARP1 to repair DNA lesions. These cancer cells are hypothesized to be highly 
sensitive to PARP inhibitors under various cellular stresses. Indeed, PARP inhibitors 
have shown more toxicity in cancer cell lines as well as human tumors with 
BRCA1/BRCA2 deficiency 221-223. In addition to DNA repair, PARP1 is actively 
involved in transcription regulation, either through directly modulating chromatin 
structure or by regulating other chromatin-modifying enzymes and transcription factors 
224,225.  
 In the current study, we extended our findings by demonstrating that doxorubicin 
treatment can enhance Snail-LSD1 interaction in a PARP1-dependent manner. In 
addition, Snail contains a potential pADPr-binding motif and is subject to poly(ADP-
ribosyl)ation. Our data also suggested that the enzymatic activity of PARP1 is required 
for Snail-LSD1 binding to the PTEN promoter; upon binding, LSD1 demethylates 
histone H3 lysine 4 at the promoter region in favor of PTEN transcription suppression 
and the downstream Akt phosphorylation. Furthermore, we found that PARP1 inhibitor 
AZD2281 can enhance the killing effect of doxorubicin on selective breast and colon 
cancer cells. Together, we proposed a new mechanism adopted by cancer cells to defend 
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themselves against DNA damage-induced apoptosis, which gives us new implications on 
the design of efficient cancer treatment strategies.   
4-2 Materials and methods 
Plasmids, antibodies and reagents 
Human cDNA for PARP1 and LSD1 were amplified from HeLa cDNA and 
respectively cloned into pCMV-Tag2B with an N-terminal Flag tag. Snail mutant was 
generated using the QuickChange Mutagenesis kit (Stratagene, La Jolla, CA) as 
described (Wu et al, 2009a). All sequences were verified by DNA sequencing. 
Antibodies against Snail, LSD1, PARP1, PTEN, Akt and Akt-P were purchased from 
Cell Signaling Technology (Danvers, MA); anti-H3K4me2 from Millipore (Bedford, 
MA); anti-Flag from Sigma-Aldrich (St Louis, MO); anti-HA from Roche Molecular 
Biochemicals (Indianapolis, IN); anti-pADPr from Trevigen (Gaithersburg, MD). 
Smartpool siRNA against human PARP1 was from Dharmacon. Doxorubicin was 
purchased from Sigma-Aldrich, Gallotannin from Santa Cruz, and AZD2281 from 
Selleck Chemicals. 
Cell cultures and transfections  
The human embryonic kidney HEK293, breast cancer MDA-MB157 and colon cancer 
HCT116 cell lines were purchased from the American Type Culture Collection 
(Manassas, VA) and grown in Dulbecco's modified Eagle's/F12 medium plus 10% fetal 
bovine serum as described previously (Wu et al, 2009a). Plasmids were transiently 
transfected into cells using FuGENE 6 (Roche Molecular Biochemicals). 48 hours after 
transfection, cells were harvested for further experiments.  
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Western blot analysis and immunoprecipitation  
For protein extraction, 5 × 105 cells per well were plated onto six-well plates, before 
protein extraction and western blot analysis. For immunoprecipitation, cells were lysed in 
buffer (50 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 5 μg/ml aprotinin, 1 μg/ml pepstatin, 
1% NP-40, 1 mmol/l EDTA and 0.25% deoxycholate). Total cell lysates (1000 μg) were 
incubated overnight with desired antibodies conjugated to agarose beads (Roche 
Molecular Biochemicals) at 4°C. The beads were then washed 5 times with PBS. The 
immunoprecipitated protein complexes were resolved by 10% SDS–PAGE, followed by 
western blot analysis.  
Chromatin immunoprecipitation  
ChIP assays were performed according to the protocol described by Nowak et al 
(2005) with some modifications. The cells were crosslinked with disuccimidyl glutarate 
(Pierce, Rockford, IL) and formaldehyde at room temperature. Cells were subjected to 
lysis with L1 buffer (50 mM Tris, 2 mM EDTA, 0.1% IGEPAL, 10% glycerol, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor 
mixture (pH 8.0)) on ice. After centrifugation, the nuclear pellet was resuspended in ChIP 
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris and protease inhibitor mixture (pH 
8.0)). Cell lysates were subjected to sonication and then incubated with 4 μg of Snail 
(Abcam), LSD1 (Sigma-Aldrich) or H3K4me2 antibody overnight, followed by 
incubation with a 50% slurry of protein A–agarose/Salmon sperm DNA (Upstate 
Biotechnology, Lake placid, NY) for 3 h at 4°C. Bound DNA–protein complexes were 
eluted and crosslinks were reversed after a series of washes. Purified DNA was 
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resuspended in TE buffer (10 mM Tris–HCl and 1 mM EDTA (pH 8.0)) for PCR. The 
primers for the PTEN promoter were 5′-CCGTGCATTTCCCTCTACAC-3′ and 5′-
GAGGCGAGGATAACGAGCTA-3′. 
Real-time quantitative PCR  
 Quantitative real-time PCR experiments were performed using SYBR Green Power Master 
Mix following the manufacturer’s protocol (Applied Biosystems). Experiments were repeated 
three times and mean ± s.d. was calculated.  
MTT assay  
 MTT assays were performed using standard protocol. Cell count was optimized. Cells 
were incubated with 10 µl MTT reagent for 2 hours before adding 100 µl DMSO reagent. 
Absorbance was detected at 570nm. Assays were repeated three times and mean ± s.d. 
was calculated.  
4-3 Results 
PARP1-Snail affinity is enhanced by doxorubicin treatment 
 Through mass-spectrometry analysis, PARP1, which has a molecular weight of 
around 116kDa, was identified besides several already known Snail partners such as 
GSK3-β, β-Trcp, PRMT5 and LSD1 (Figure 4.1A). The roles of PARP1 in DNA damage 
repair as well as transcription regulation make it a promising candidate for investigating 
the mechanism of Snail-mediated PTEN suppression and cell survival. To confirm the 
physical interaction of Snail-PARP1, we next performed co-immunoprecipitation 
experiments using HEK293 cells over-expressing Snail-HA and Flag-PARP1, as well as 
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breast cancer cell line MDA-MB-157 and colon cancer cell line HCT116. As shown in 
Figure 4.1B and 4.1C, Snail and PARP1 proteins showed relatively modest interaction in 
all of the three cell lines. Interestingly, the protein interaction was significantly enhanced 
when the cells were treated with doxorubicin, indicating that upon activation, PARP1 
becomes tightly associated with Snail.   
PARP1 positively regulates Snail-LSD1 interaction through poly(ADP-ribosyl)ation 
of Snail  
 Since we have recently demonstrated that Snail and LSD1 can form a repressor 
complex, we examined if PARP1 can mediate the association of Snail with LSD1. In 
HEK293 cells overexpressing Snail and LSD1, doxorubicin treatment significantly 
enhanced Snail-LSD1 binding, and similar results could be obtained by co-expressing 
PARP1 in the cell (Figure 4.2A). In MDA-MB-157 and HCT116 cells, while doxorubicin 
consistently had positive effect, either PARP1 knockdown or treatment of PARP1 
inhibitor AZD2281 significantly reduced Snail-LSD1 affinity (Figure 4.2B). These 
results indicated that PARP1 promotes the formation of the Snail-LSD1 complex. It 
would be interesting to find out the specific mechanism by which PARP1 mediates the 
protein interaction.      
 Through sequence alignment we identified three highly conserved residues Arg151, 
Lys152 and Ala153 of Snail protein to be in concert with the corresponding residues of 
the previously established pADPr binding motif, in which the positively charged lysine 
and arginine are strictly followed by either one of alanine, isoleucine, leucine and valine 
(Figure 4.3A). While the sequence surrounding Arg151, Lys152 and Ala153 does not 
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exactly follow the rule for the composition of pADPr-binding motif as refined by Gagne 
and colleagues, the presence of the most essential residues (Arg151, Lys152) indicates 
the potential pADPr docking site on Snail protein. Considering that PARP1 became 
activated and tightly bound to Snail upon DNA damage, we went on to investigate 
whether Snail can interact with PARP1 through its potential pADPr-binding motif. First 
we generated Snail point mutant R151A/K152A and examined its interaction with 
PARP1. As shown in Figure 4.3B, the mutant significantly lost PARP1 binding affinity 
compared to wild-type Snail, indicating that R151, K152 are critical for PARP1 
association. Interestingly, the Snail mutant also significantly lost the binding affinity for 
LSD1, further confirming that the presence of PARP1 is required for Snail-LSD1 
association (Figure 4.3C). Consistently, when the cells were treated with gallotannin, an 
inhibitor of poly(ADP-ribose) glycohydrolase (PARG) which catalyzes the degradation 
of pADPr, the association of Snail-LSD1 was significantly enhanced (Figure 4.3D). 
Furthermore, the Snail mutant became less stable compared to the wild-type protein 
(Figure 4.3E), which was in accord with our previous finding that formation of Snail-
LSD1 complex was required for maintaining the stability of each component 142.   
 Upon activation, PARP1 functions by attaching pADPr chain on specific glutamate, 
aspartate or lysine residues of its target proteins. To investigate whether Snail can 
undergo poly(ADP-ribosyl)ation upon association with PARP1, we immunoprecipitated 
Snail protein from the abovementioned stable HEK293 cells, and performed western-blot 
using antibody against pADPr. As shown in Figure 4.3F, Snail protein was poly(ADP-
ribosyl)ated, the effect of which could be enhanced by doxorubicin and suppressed by 
AZD2281. There was no significant difference in regard to the level of poly(ADP-
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ribosyl)ation on wild type and the R151A/K152A mutant Snail (data not shown), 
suggesting the existence of multiple modification sites on Snail protein. Together, we 
demonstrated that (1) PARP1 positively mediates Snail-LSD1 association as well as their 
protein stability through interacting with a potential pADPr-binding motif of Snail; and 
(2) Snail protein is subject to PARP1-mediated poly(ADP-ribosyl)ation on multiple 
residues.  
The enzymatic activity of PARP1 is required for Snail-LSD1 binding to PTEN 
promoter  
 Previous studies have demonstrated that Snail can bind to PTEN promoter to repress 
its transcription. The formation of Snail-LSD1-PARP1 complex under DNA damage 
condition prompted us to investigate how these proteins potentially cooperate to 
downregulate PTEN in favor of cancer cell survival. Since Snail interacts with LSD1 
through its SNAG domain, we reasoned that Snail can recruit LSD1 to PTEN promoter 
for H3K4 demethylation and gene suppression. We then performed chromatin 
immunoprecipitation (ChIP) assays to test this hypothesis. Indeed, both Snail and LSD1 
could interact with PTEN promoter in MDA-MB-157 and HCT116 cells (Figure 4.4A). 
Interestingly, the binding affinity was significantly increased upon doxorubicin treatment, 
indicating that PARP1 becomes activated in response to DNA-damaging agent and 
promotes the interaction of Snail/LSD1 with PTEN promoter. Also as expected, 
AZD2281 treatment or PARP1 knockdown negatively regulated the complex-promoter 
binding. Consistently, the level of H3K4 methylation on PTEN promoter was increased 
upon AZD2281 treatment or PARP1 knockdown, and was decreased upon doxorubicin 
treatment, further confirming that PAPR1 facilitates the access of LSD1 to PTEN 
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promoter (Figure 4.4B). The ChIP samples were also analyzed by quantitative real-time 
PCR and similar results were obtained (Figure 4.4C). These results are not only 
supported by our earlier data showing that upon poly(ADP-ribosyl)ation of Snail, the 
complex becomes stabilized (Figure 4.3E), but also in line with the notion that Snail 
works together with corepressors to downregulate PTEN in response to DNA damage, in 
such way that Snail fulfils its function as a survival factor.     
PARP1 inhibitor AZD2281 enhances the killing effect of doxorubicin on cancer cells  
 Consistent with the results that doxorubicin enhanced the binding of the Snail-LSD1 
repressor complex to PTEN promoter, we found that the protein level of PTEN was 
decreased in MDA-MB-157 and HCT116 cells upon doxorubicin treatment (Figure 4.5A, 
lane 3). Also as expected, the level of Akt phosphorylation was increased by doxorubicin. 
In contrast, AZD2281 treatment had the opposite effect on PTEN expression as well as 
Akt phosphorylation (Figure 4.5A, lane 2). Strikingly, when cells were treated with the 
two drugs simultaneously, the effect of doxorubicin on PTEN suppression as well as Akt 
phosphorylation was compromised by AZD2281 (Figure 4.5A, lane 4). To further test the 
idea that cancer cells apply a Snail complex-mediated defensive mechanism to evade 
DNA damage-induced apoptosis, we applied doxorubicin in combination with AZD2281 
to cancer cells and examined their viability. As seen in Figure 4.5B, either doxorubicin or 
AZD2281 treatment can reduce the overall viability of MDA-MB-157 and HCT116 cells; 
the number of living cells was further decreased upon treatment of both drugs, indicating 
that the drug combination has enhanced cell killing effect. Taken together, our results 
suggest that blocking the activity of PARP1 can overcome the effect of doxorubicin on 
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PTEN suppression and Akt activation, and sensitize cancer cells to the cytotoxic effect of 
doxorubicin.  
4-4 Discussion 
 In this study, we demonstrated that through interacting with and poly(ADP-
ribosyl)ating Snail, PARP1 promotes the formation of Snail-LSD1 repressive complex 
and enhances the binding of the complex to PTEN promoter for transcription 
suppression. Previously we have shown that Snail uses its highly conserved SNAG 
domain as a histone mimicking “hook” to recruit LSD1 to its target gene promoters 142. 
The involvement of PARP1 in this regulation process particularly under the condition of 
DNA damage adds another layer to this delicate transcriptional machinery. As the 
founding member of the PARP superfamily, PARP1 is a multifunctional protein that not 
only plays a role in DNA repair, but also participates in gene transcription regulation. The 
effect of PARP1 could either be stimulatory or inhibitory, depending on the specific 
environmental context and cellular signals. In the very case discussed here, PAPR1 
functions as a co-inhibitor of the Snail-LSD1 complex under DNA damage condition. 
Upon activation by doxorubicin, PARP1 uses its pADPr for association with the pADPr-
binding motif of Snail, and furthermore promotes the interaction of Snail with LSD1 
(Figure 4.2 and 4.3A). Disruption of the pADPr-binding motif by point mutation not only 
resulted in loss of Snail-PARP1 association (Figure 4.3B), but also strikingly 
compromised Snail-LSD1 complex formation (Figure 4.3C). Consistently, blocking the 
degradation of pADPr by inhibiting PARG could enhance Snail-LSD1 interaction (Figure 
4.3D). In addition, we found that Snail could undergo poly(ADP-ribosyl)ation on DNA 
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damage condition (Figure 4.3F). Based on these results, together with previous finding 
that Snail interacts with LSD1 through its SNAG domain, we reasoned that binding and 
modification of Snail by PARP1 could change the conformation of Snail and potentially 
expose its LSD1-binding motif on the SNAG domain to facilitate Snail-LSD1 interaction. 
Therefore, LSD1 can be recruited by Snail to the target gene (PTEN in this case) 
promoter, where it demethylates histone H3 lysine 4 in favor of transcription repression 
(Figure 4.4 and 4.5A). The model provided here illustrated a tantalizing mechanism of 
how cancer cells defense themselves against DNA damage and try to evade PTEN-
mediated apoptosis (Figure 4.6). A detailed computer-based structure analysis would 
hopefully further illustrate this dynamic regulatory process and will be done in the near 
future. We also tried to explore our findings by specifying the residues on Snail protein 
that are subject to poly(ADP-ribosyl)ation. Mutation of the lysine residue on the pADPr-
binding motif of Snail did not significantly compromise the level of poly(ADP-
ribosyl)ation, neither did mutations on Lys9, Asp12 or Lys16 of SNAG domain (data not 
shown), indicating that Snail can undergo poly(ADP-ribosyl)ation on multiple residues, 
which remain to be defined in the future. Together, our study illustrated the cooperation 
of Snail, LSD1 and PARP1 in PTEN transcription suppression under DNA damage 
condition. Previous to our study, there have been reports demonstrating the dynamic roles 
of PARP1 in gene transcription regulation. For example, upon binding to nucleosomes, 
PARP1 may regulate the compaction/decompaction of chromatin 226,227; PARP1 may also 
exclude histone H1 from its target gene promoters in favor of transcription activation 228. 
In addition, PARP1 has been shown to interact noncovalently with DNA 
methyltransferase 1 (Dnmt1) and inhibit its enzymatic activity, in such way that it 
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regulates genomic methylation patterns 229. As another typical example, PARP1 can 
dissociate Smad complexes from DNA through poly(ADP-ribosyl)ating Smad3 and 
Smad4, therefore attenuating Smad-mediated transcription and inhibiting TGF-β-induced 
epithelial-mesenchymal transition (EMT) 230. Since we have demonstrated before the 
function of Snail-LSD1 on E-cadherin suppression and EMT induction, there is definite 
possibility that PARP1 also participates in this regulation process. In contrast to the 
Smad-PARP1 model, however, poly(ADP-ribosyl)ation of Snail by PARP1 would rather 
enhance the inhibitory effect of Snail-LSD1 on E-cadherin and promote EMT. We reason 
that in different biological settings, cells may rely on different transcriptional machineries 
to turn on or off the expression of specific genes in response to various signals, or for the 
adaptation of different extracellular and intracellular stresses. Our hypothesis is further 
supported by recent finding that PARP1 can poly(ADP-ribosyl)ate and stabilize Snail and 
promote Snail-mediated EMT 231. We speculate that PARP1 regulates Snail-mediated 
EMT using a more complicated and delicate mechanism, probably through promoting the 
recruitment or release of other histone-modifying enzymes and cofactors (LSD1 for 
example) to further modify chromatin. Since both E-cadherin and PTEN loss can 
promote the generation of cancer stem cells, another intriguing question is to what extent 
the Snail-LSD1-PARP1 complex contributes to cell stemness. While more work is still 
needed for clarification of the whole mechanism, our current study provides important 
information for the completion of the model of Snail-mediated transcription regulation.  
 The second insight provided by our study lies in the finding that PARP inhibitors in 
conjunction with DNA-damaging agents may represent an effective treatment strategy 
against a much wider range of cancers. While the conventional chemotherapeutic drugs 
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such as doxorubicin function by targeting DNA synthesis and cell division, unfortunately 
they are not smart in pinpointing cancer cells; rather they also do harm to normal cells 
with rapid dividing property. Even worse, many solid tumors continually undergoing 
chemotherapy will ultimately acquire drug resistance. On the other hand, the targeted 
therapy including small molecule inhibitors and monoclonal antibodies may circumvent 
the unamiable cytotoxic effects and attack tumor cells with more accuracy and efficiency. 
Many cancer cells have defective DNA repair pathways. For example, BRCA1/2 
mutations are found in breast and ovarian cancers 232,233, and mutations of ataxia 
telangiectasia mutated (ATM) gene are identified in lymphoid malignancies 234. In this 
regard, targeting DNA repair machineries is a promising strategy for cancer treatments. 
Indeed, PARP inhibitors are prevailingly considered as treatment options against 
BRCA1/2-deficient tumors due to the synthetic lethality effect 221-223. Under the same 
rationale, PARP1 inhibitors are also used in the treatment of tumors deficient in PTEN, 
which plays a critical role in the expression of the repair protein RAD51 235. Currently, 
different PARP inhibitors combined with DNA-damaging agents are under investigation 
in several clinical trials 236. We have shown in our study the enhanced killing effect of 
doxorubicin-AZD2281 combination on BRCA1/2 and PTEN intact MDA-MB-157 and 
HCT116 cells (Figure 4.5B). Based on our results, we argue that in addition to the 
induction of DNA damage, doxorubicin treatment also enhances Snail-LSD1 mediated 
PTEN suppression in a PARP1-dependent manner, which results in phosphorylation and 
activation of pro-survival Akt. Inhibition of PARP1 can compromise this undesirable 
effect while synergizing the DNA-damaging effect of doxorubicin to efficiently kill 
cancer cells. While in vivo experiments are required to consolidate our results as well as 
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to evaluate the long-term effect of PARP1 inhibition, our data expands potential 
therapeutic benefits of PARP1 inhibitors, especially on tumors with high levels of Snail 
and LSD1 expression. Furthermore, it is interesting to see if PARP1 inhibitors can 
synergize with LSD1 inhibitors and novel SNAG domain-mimicking compounds that 
block Snail-LSD1 interaction to treat these kinds of cancers 237.  
 In summary, we demonstrated that PARP1-mediated poly(ADP-ribosyl)ation of Snail 
is critical for Snail-LSD1 complex formation and the downstream PTEN suppression. 
Due to the highly heterogeneous and instable nature of cancer cells, as well as the 
complexity of the surrounding context, among different cancer cells there is huge 
discrepancy in regard to the sensitivity to a specific drug, making it impractical to find a 
one-cure-fits-all therapy. The development of efficient treatment strategies would heavily 
rely on the understanding of the signaling mechanisms adopted by cancer cells to 
overcome the adverse environment for survival. Our study not only provides a new 
insight into the working mechanism of the Snail transcriptional machinery, but also 
explores the potential application of PARP inhibitors in conjunction with DNA damage-
inducing agents in targeting cancer cells. As PARP inhibitors are thrust into the limelight 
by the encouraging results of early clinical trials, our study would provide extra impetus 
for future drug development and help to diversify cancer treatment strategies. 
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Figure 4.1 Doxorubicin enhances PAPR1-Snail interaction.  
(A) The Snail complex was isolated from the stable HEK293 cells overexpressing dual-
tagged Snail (HEK293-SN) by two-step immunopurification. The complex were 
separated on SDS–PAGE and visualized by silver staining. LSD1 and PARP1 were 
identified by mass spectrometry. (B) Flag-tagged PARP1 and HA-tagged Snail were co-
expressed in HEK293 cells. After immunoprecipitation of PARP1, bound Snail was 
examined by western blotting. 1 µM of doxorubicin (DOX) was treated 6 hours before 
harvesting cells. (C) Endogenous PARP1 was immunoprecipitated from MDA-MB157 
and HCT116 cells and bound endogenous Snail was examined by western blotting. The 
same doxorubicin treatment condition was used.   
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Figure 4.2 PAPR1 positively regulates Snail-LSD1 interaction.  
(A) Flag-tagged LSD1 and HA-tagged Snail were co-expressed in HEK293 cells. After 
immunoprecipitation of LSD1, bound Snail was examined by western blotting. For 
comparison, cells were either co-expressed with Flag-tagged PARP1 (lane 2) or treated 
with 1 µM of doxorubicin 6 hours before harvesting cells (lane 3). (B) Endogenous LSD1 
was immunoprecipitated from MDA-MB157 and HCT116 cells and bound endogenous 
Snail was examined by western blotting. For comparison, cells were treated with 
doxorubicin (1 µM for 6 hours, lane 2), AZD2281 (2µM for 24 hours, lane 3), or 
transfected with PARP1 siRNA (lane 4).  
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Figure 4.3 Snail contains a potential pADPr-binding motif and is subject to poly(ADP-
ribosyl)ation.  
(A) Sequence alignment of Snail protein with previously established pADPr-binding 
motif. The concert residues were highlighted with red color. (B) Flag-tagged PARP1 was 
co-expressed with HA-tagged wild-type or mutant (151 R151A/K152A) Snail in 
HEK293 cells. After immunoprecipitation of PARP1, the bound Snail was examined. For 
comparison, cells were treated with doxorubicin as indicated. (C) Flag-tagged LSD1 was 
co-expressed with HA-tagged wild-type or mutant Snail. After immunoprecipitation of 
LSD1, the bound Snail was examined.  (D) Flag-tagged LSD1 was co-expressed with 
HA-tagged wild-type Snail. After immunoprecipitation of PARP1, the bound Snail was 
examined. For comparison, cells were treated with 10 µM of gallotannin (GN) for 6 
hours (lane 2). (E) Wild-type or mutant Snail was respectively expressed in HEK293 
cells and treated with 10 mg/ml of cycloheximide (CHX) for different time intervals. The 
level of Snail was analyzed by western blotting. Densitometry results were statistically 
analyzed and plotted (bottom panel, mean ± SD from 3 separate experiments). A 
representative western blotting experiment is shown in the top panel. (F) Snail protein 
was immunoprecipitated from HKE293-SN, and  western blotting was performed using 
antibody against pADPr. For comparison, cells were treated with doxorubicin and 
AZD2281.   
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Figure 4.4 The enzymatic activity of PARP1 is required for Snail-LSD1 binding to 
PTEN promoter.  
(A) The association of endogenous Snail and LSD1 with the PTEN promoter was 
analyzed by chromatin immunoprecipitation (ChIP) assay in MDA-MB157 and HCT116. 
For comparison, cells were treated with doxorubicin or AZD2281, or transfected with 
PARP1 siRNA. (B) Methylation of H3K4 on the PTEN promoter was analyzed by ChIP 
assay using antibody against H3K4me2. For comparison, cells were treated with 
doxorubicin or AZD2281, or transfected with PARP1 siRNA. (C) The ChIP samples 
were analyzed by quantitative real-time PCR (mean ± SD from three separate 
experiments).  
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Figure 4.5 AZD2281 enhances the killing effect of doxorubicin on cancer cells.  
(A) MDA-MB157 and HCT116 cells were treated with AZD2281, doxorubicin, or these 
two drugs together (A/D), and endogenous levels of PTEN, Akt and phosphorylated Akt 
(Akt-P) were examined by western blotting. (B) MTT assays were performed using 
MDA-MB157 and HCT116 cells and the overall cell viability was determined (mean ± 
SD from three separate experiments).  
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Figure 4.6 A proposed model illustrating that Snail recruits LSD1 to PTEN promoter in a 
PARP1-dependent manner.  
Under DNA damage condition, Snail becomes tightly associated with PARP1 and is 
subject to PARP1-mediated poly(ADP-ribosyl)ation, which would potentially change the 
protein conformation of Snail and promote its association with LSD1. Therefore LSD1 
can be recruited by Snail to PTEN promoter for transcription repression. This provides an 
alternative mechanism by which PARP1 mediates tumor cell survival.  
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Chapter 5: Overall discussion and future plans 
 Epigenetic deregulation contributes significantly to the development of multiple 
human cancers. Accordingly, epigenetic therapy emerges as a novel weapon to fight 
against cancer. In particular, there has been growing popularity of chromatin-modifying 
enzymes as therapeutic targets, given their nature of diversity and substrate specificity. 
While earlier research focused on their function on histones, recent studies have 
demonstrated that nonhistone proteins can also become the targets of these enzymes 238-
242. This adds another layer to the still elusive mechanism governing the epigenetic 
regulation process. As the expansion of the list of nonhistone proteins that are subject to 
post-translational modifications in a similar pattern to that of histones, a range of critical 
questions emerged: What is the determinant, or driving force, for histone-modifying 
enzymes to target certain groups of nonhistone proteins? What is the biological 
consequence of histones and nonhistone proteins “sharing” specific enzymes? Does the 
“histone code” hypothesis also apply to nonhistone proteins? How do the modifications 
of nonhistone proteins potentially coordinate with those of histones to regulate gene 
transcription under certain biological circumstances? And going further beyond the level 
of molecular biology, does this “enzyme sharing” give us any medical implications?   
 In our study, we demonstrated that the SNAG domain of Snail mimics the histone H3 
tail and functions as a “molecular hook” for recruiting LSD1. We further showed that 
disruption of Snail and LSD1 interaction can derepress E-cadherin expression and inhibit 
EMT induction. Our study provides a novel model revealing the linkage between 
transcriptional control and epigenetic regulation, which ideally addresses the above 
questions. The histone mimicking strategy has actually been applied by different 
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organisms. In a recent study on chromosome segregation dynamics during mitosis, Kelly 
and colleagues demonstrated that Thr3 phosphorylation on histone H3, a hallmark of 
mitosis, is recognized by the Survivin subunit of the chromosomal passenger complex 
(CPC) 243, which is an essential modulator of chromosome segregation 244. The H3-
Survivin interaction, based on their results, mediates the recruitment of the CPC to 
chromosomes. Jeyaprakash and colleagues further demonstrated that a phospho-mimic N-
terminal sequence, which is also found in several mitotic proteins including human 
Shugoshin 1, is responsible for Survivin binding 245. The identification of the epitopes 
present in both the histone H3 and several mitotic proteins indicated their mutually 
exclusive interactions with the CPC 245. Together, these studies offer us a clue: histone 
mimicry also applies to mitotic-associated proteins and contributes to the fine-tuning of 
cell division process. Even in the world of microorganisms, histone mimicry may be 
adopted by some pathogens 246. Given the presence of histone-mimicking proteins based 
on genome analysis of multiple viruses, it is possible that these viruses can use similar 
strategies to hijack the host epigenetic program. Indeed, Tarakhovsky and colleagues 
found that the immunosuppressive NS1 protein of the H3N2 strain of influenza A virus 
contains the same sequence as that of human histone H3 tail 247. They argued that by 
mimicking the histone H3 tail, the virus gains access to the host chromatin to target a set 
of proteins in the nucleus, therefore impairing the antiviral host cell response. 
Considering the far more complicated genomes of mammalians, especially we human 
beings, histone mimicry may lurk in much wilder territories than expected. Clarification 
of the mechanisms as well as biological functions of histone mimicry will provide 
valuable information for the development of small molecule drugs. In the specific case of 
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Snail/LSD1-mediated EMT and metastasis, we are currently applying computer modeling 
followed by biological screening assays to define SNAG-mimicking compounds that 
efficiently disrupt Snail-LSD1 connection. Based on the current progress, we are 
confident to identify some promising candidates for further functional testing.  
 Besides compound screening, we will continue to further investigate Snail-directed 
epigenetic regulation that contributes to cancer development. In basal-like breast cancer 
(generally referred to as triple-negative breast cancer) that has typical EMT 
characteristics and high metastatic potential 248-252, DNA methylation at the E-cadherin 
promoter is not uncommon. What is the driving force for DNMTs to methylate DNA at 
the E-cadherin promoter? What are the epigenetic events that happen before the long-
term repression by DNA methylation takes effect? How can Snail organize these 
epigenetic events into a hierarchic fashion to eventually boost promoter DNA 
methylation in specific biological context of EMT? To answer these questions, not only 
should we decipher the potential built-in connection between histone modifications and 
DNA methylation, we also need to characterize the role of the linker, i.e. Snail, during 
this dynamic cellular event. As mentioned, Snail has been shown to associate with 
multiple complexes containing distinct histone-modifying activities, such as the 
HDAC1/2-containing SIN3 complex, the PRC2 complex with histone H3 lysine 27 
trimethylase activity, and the LSD1/CoREST complex. Most recently, studies from our 
lab demonstrated that Snail can interact with histone H3 lysine 9 (H3K9) 
methyltransferase G9a  and is required for the enrichment of G9a and corresponding 
H3K9 dimethylation (H3K9me2) at the E-cadherin promoter 253. The study also showed 
that Snail interacted with DNMT1, DNMT3a and DNMT3b in a G9a-dependent manner. 
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Interestingly, H3K9me2 was found to coincide with DNA methylation at the E-cadherin 
promoter, and knockdown of G9a expression significantly inhibited DNA methylation at 
the promoter region and reactivated E-cadherin expression in MDA-MB-231 breast 
cancer cells. The study strongly suggests that Snail-mediated H3K9me2 by G9a is one of 
the key events in the maintenance of E-cadherin promoter silencing. 
 In addition to G9a, our lab found another histone methyltransferase Suv39H1 can 
interact with Snail 254. Furthermore, the interaction is mediated by the SNAG domain and 
is critical for H3K9 trimethylation (H3K9me3) on the E-cadherin promoter in breast 
cancer cells.  It has been demonstrated that Suv39H1-mediated H3K9me3 creates a 
docking site for the adaptor molecule HP1, which in turn recruits DNMT3b and HDAC 
to respectively catalyze DNA methylation and histone deacetylation 44. Consistent with 
these findings, our lab showed that increased H3K9me3 is accompanied by decreased 
acetylation of H3K9 and increased DNA methylation on the E-cadherin promoter, and 
knockdown of Suv39H1 can reverse these events and reactivate E-cadherin expression. 
Together, the study indicated the critical role of Suv39H1 during Snail-mediated E-
cadherin suppression.  
 The interaction of Snail with G9a and Suv39H1 gave us a couple of implications. 
Methylation on H3K9 is a sequential process, with the lysine residue subject to 
modifications of up to three methyl groups. While G9a catalyzes the mono- and 
dimethylation processes, Suv39H1 uses the product of G9a as substrate, and further 
converts it into H3K9me3 255,256. We reasoned that G9a and Suv39H1 cooperate to 
establish the silencing heterochromatin at the E-cadherin promoter, typically with the 
help of Snail. Furthermore, there seems to be two distinct routes for H3K9 
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methyltransferases to promote DNA methylation at the E-cadherin promoter. In the first 
route, G9a directly interacts with DNMTs and recruits them to the E-cadherin promoter 
through the association with Snail. In the second route, both G9a and Suv39H1 rely on 
their catalytic activities to respectively create H3K9me2 and H3K9me3, with both marks 
being able to recruit HP1 and DNMTs to the promoter area 257. This dual-mode of 
regulation may provide a double safety to guarantee the efficient methylation of E-
cadherin promoter.  
 Taken together, it becomes clear that Snail manipulates epigenetic outputs and 
masters EMT in a multi-step fashion. First, Snail uses its molecular hook, i.e. the SNAG 
domain, to recruit complexes containing LSD1 and HDACs to E-cadherin promoter, 
where they create an initial repressive chromatin environment, i.e. H3K4 demethylation 
and H3/H4 deacetylation. Previous studies indicated that H3K9me2/3 and H3K4me2/3 
are mutually exclusive, due to the fact that H3K9 methyltransferases including G9A and 
Suv39H1 fail to bind and methylate H3K4me2/3 substrates 258,259. We reasoned that 
demethylation of H3K4 by LSD1 provides a condition that favors Snail-mediated 
association of G9a and Suv39H1 on the E-cadherin promoter. In the meanwhile, HDACs 
may mediate the interaction of PRC2 with Snail, therefore promoting PRC2 to land in the 
promoter region. Second, G9a associates with the C-terminal region of Snail and is 
brought to the promoter region for H3K9me2, while Suv9H1 is drafted by the SNAG 
domain to land in the chromatin and uses H3K9me2 as substrate to generate H3K9me3. 
Since H3K9 methylation and acetylation are considered mutually exclusive, the level of 
acetylation would be further decreased. Third, the recruitment of G9a and Suv39H1 
serves as an intermediate step that bridges the initial H3K4 demethylation to the last 
107 
 
modulation event, as it facilitates promoter DNA methylation by DNMTs. Collectively, a 
picture appears in which Snail coordinates multiple epigenetic events to function in great 
synergy to suppress E-cadherin and induce EMT (Figure 5.1).   
 As our knowledge on Snail transcriptional machinery continues growing, there are 
still many mechanistic details that remain to be clarified. Firstly, after binding and 
bringing enzymes to chromatin, how will the SNAG domain get released to make room 
for histones? While we hypothesized that it is overabundant amount of histone proteins at 
the chromatin region that outcompetes the binding of the SNAG domain, further 
experiments are required to address this issue. Secondly, we are wondering whether the 
SNAG domain can be modified by chromatin enzymes such as LSD1 and PARP1 on 
specific residues. Development of antibodies specifically recognizing SNAG domain 
with different modifications would help to clarify this question. Once specific 
modifications on the SNAG domain are identified, we can take one step further to find 
out how these modifications may affect the series of epigenetic events leading to EMT. 
Alternatively, we can perform paralleled pulldown assays using SNAG peptides with 
different modifications, and compare the pulldown proteins with those binding to 
unmodified SNAG peptide. The distinct proteins, particularly those with chromatin-
modifying activities, that identified from each assay will give us some clues and direct 
our future studies. Thirdly, while PRC2-mediated H3K27me3 is associated with gene 
repression, its enrichment is unexpectedly anti-correlated with DNA methylation 260,261. It 
is hypothesized that the expression of some developmentally important genes is governed 
by an “epigenetic switching” reprogramming event. Basically, these genes are repressed 
by PRC2 in normal cells, whereas they are subject to hypermethylation in cancer 262. 
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While the specific mechanism remains unclear, this hypothesis is compatible with our 
model that PRC2 recruitment precedes the approaching of DNMTs during cancerous 
EMT, and may partially explain the reduced epigenetic plasticity and permanent silencing 
of E-cadherin in multiple cancers. Further studies would help to clarify the role of PRC2 
in Snail-mediated epigenetic modulation cascade in specific biological settings.  
 Clarification of Snail-mediated epigenetic regulation will provide molecular basis for 
future drug development and help to diversify cancer treatment strategies. Most recently, 
Schenk and colleagues applied LSD1 inhibitor tranylcypromine (TCP) in combination 
with all-trans retinoic acid (ATRA) therapy to efficiently sensitize acute leukemia of 
myeloid (AML) cells to undergo differentiation and decrease their leukemia-initiating 
capability in human xenograft models 263. Consistently, the studies of Harris and 
colleagues also indicated the therapeutic potential of LSD1 inhibitors on AML, albeit the 
long-term effect of LSD1 inhibitors remains to be evaluated 264. In addition, inhibitors 
targeting histone methyltransferases including G9a are under development and will 
potentially enter clinical trials in the coming years 265. Considering the hierarchic and 
interdependent nature of the EMT regulation program, SNAG-mimicking compounds 
may efficiently interrupt this epigenetic modulation cascade by competing with Snail for 
binding of histone-modifying enzymes such as LSD1, HDACs and Suv39H1, therefore 
inhibiting their recruitment by Snail to the E-cadherin promoter. In this regard, these 
compounds might work in great synergy with other treatment strategies for the cure of 
patients with EMT-related diseases. Extra attention should be paid to evaluate the 
pharmacokinetic as well as pharmacodynamic properties of these drugs, especially when 
they are combined together to cause potential drug interactions.    
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 In the third part of our study, we demonstrated that PARP1-mediated poly(ADP-
ribosyl)ation of Snail is required for interaction with LSD1, as well as recruitment of 
Snail/LSD1 complex to PTEN promoter. Our study provides a more detailed epigenetic 
mechanism of how Snail transcriptionally represses PTEN to mediate tumor survival. 
While it remains to be seen if PARP1 is also involved in Snail/LSD1-mediated E-
cadherin suppression, our findings added another layer to the delicate Snail 
transcriptional machinery and further illustrated Snail as a multi-functional protein 
bridging transcriptional control and epigenetic regulation during cancer development. 
While further in vivo studies are still pending, our current data indicated that PARP1 
inhibitors might be combined with conventional chemo drugs to more efficiently target 
cancer cells with high expression of Snail and LSD1.   
 To conclude, our study has provided new mechanistic details as well as therapeutic 
implications of Snail-mediated epigenetic events contributing to cancer development. 
Beyond our study, the refreshing Snail story reminds us of the intricacy as well as 
integrity of the epigenetic network, and it really prompts me to dig further into the 
immense world of epigenetics. With the deluge of modern molecular technology and the 
tremendous effort being made while we continue our research, we will eventually be able 
to take command over epigenetic deregulation for the great cause of conquering cancer.  
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Figure 5.1 Snail mediates multiple epigenetic events in a hierarchic fashion to suppress 
the transcription of E-cadherin .  
Through sequential interactions with LSD1/HDAC, PRC2, G9a and Suv39H1, Snail 
manages to recruit these repressor machineries to the E-cadherin promoter to modulate 
chromatin, and eventually promote DNMT-mediated promoter DNA methylation and 
gene silencing. 
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